Dong-A 
Welcome,         Profile    Billing    Logout  
 37 Products   12 Diseases  37 Products   64 Trials   1435 News 
80 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Sugarnon (evogliptin) / Dong-A
EVOMETA, NCT04706637: A Clinical Trial to Evaluate the Bone Metabolism and the Blood Sugar of Evogliptin and Dapagliflozin

Not yet recruiting
4
120
RoW
Evogliptin, Dapagliflozin
Kyung Hee University Hospital at Gangdong, Dong-A ST Co., Ltd.
Bone Diseases, Metabolic, Diabetes Mellitus, Type 2
01/22
01/23
NCT04584242: Clinical Trials to Compare the Effects of Pioglitazone and Evogliptin on Hepatic Fibrosis in Patients With Chronic Hepatitis B With Significant Hepatic Fibrosis With Type 2 Diabetes

Recruiting
4
40
RoW
gluconon tab 15mg, suganon tab 5mg
Yonsei University
Chronic Hepatitis B With Significant Hepatic Fibrosis With Type 2 Diabetes
05/22
05/22
NCT05473806: Effects of Pioglitazone and Evogliptin on Hepatic Fibrosis in Patients With Chronic Hepatitis B With Type 2 Diabetes

Active, not recruiting
4
28
RoW
Pioglitazone 15 Mg Oral Tablet, Gluconon tablet 15mg, Evogliptin 5mg, SUGANON tablet 5mg
Seung Up Kim
Hepatitis B, Chronic, Fibrosis, Liver, Diabetes Mellitus, Type 2
01/23
02/23
NCT04521452: Randomized, Open-label Trial of Inhibitory Effect of Evogliptin on Progression of CAVD

Not yet recruiting
4
218
RoW
Evogliptin
Asan Medical Center, REDNVIA
CAVD
09/24
09/24
NCT05143177: A Study to Evaluate the Efficacy and Safety of DA-1229 (Evogliptin) in Patient's Calcific Aortic Valve Disease With Mild to Moderate Aortic Stenosis (EVOID-AS)

Recruiting
2/3
580
Canada, US
Evogliptin, DA-1229, Placebo
REDNVIA Co., Ltd.
Calcific Aortic Valve Disease
05/26
12/26
NCT04055883: Clinical Study to Evaluate Efficacy and Safety of DA-1229 in Patients With CAVD

Completed
2
228
RoW
DA-1229
Dong-A ST Co., Ltd.
Calcific Aortic Valve Disease
02/23
02/23
NCT05817097: Effect of Dipeptidyl-4 Inhibitors in Reducing Stroke Severity, From HIRA Database

Not yet recruiting
N/A
22119
NA
Dipeptidyl peptidase-4 inhibitor, A10BH07, EVOGLIPTIN, Suganon Tab
Ajou University School of Medicine, Dong-A ST Co., Ltd.
Cerebral Infarction, Infarction, Brain, Dipeptidyl-Peptidase IV Inhibitors
12/24
12/24
Growtropin-II (somatropin biosimilar) / Dong-A
NCT04798690: Long-term Safety and Effectiveness of Growtropin®-II Treatment in Children With Short Stature

Recruiting
N/A
2500
RoW
Dong-A ST Co., Ltd.
Growth Hormone Deficiency, Idiopathic Short Stature, Turner Syndrome, Small for Gestational Age
12/31
12/31
Dulastin (tripegfilgrastim) / Dong-A
SWOG S1826, NCT03907488: Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma

Active, not recruiting
3
994
Canada, US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Brentuximab Vedotin, ADC SGN-35, Adcetris, Anti-CD30 Antibody-Drug Conjugate SGN-35, Anti-CD30 Monoclonal Antibody-MMAE SGN-35, Anti-CD30 Monoclonal Antibody-Monomethylauristatin E SGN-35, cAC10-vcMMAE, SGN 35, SGN-35, SGN35, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Dacarbazine, 4-(Dimethyltriazeno)imidazole-5-carboxamide, 5-(Dimethyltriazeno)imidazole-4-carboxamide, Asercit, Biocarbazine, Dacarbazina, Dacarbazina Almirall, Dacarbazine - DTIC, Dacatic, Dakarbazin, Deticene, Detimedac, DIC, Dimethyl (triazeno) imidazolecarboxamide, Dimethyl Triazeno Imidazol Carboxamide, Dimethyl Triazeno Imidazole Carboxamide, dimethyl-triazeno-imidazole carboxamide, Dimethyl-triazeno-imidazole-carboximide, DTIC, DTIC-Dome, Fauldetic, Imidazole Carboxamide, Imidazole Carboxamide Dimethyltriazeno, WR-139007, Doxorubicin Hydrochloride, 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI), ADM, Adriacin, Adriamycin, Adriamycin Hydrochloride, Adriamycin PFS, Adriamycin RDF, ADRIAMYCIN, HYDROCHLORIDE, Adriamycine, Adriblastina, Adriblastine, Adrimedac, Chloridrato de Doxorrubicina, DOX, DOXO-CELL, Doxolem, Doxorubicin HCl, Doxorubicin.HCl, Doxorubin, Farmiblastina, FI 106, FI-106, FI106, hydroxydaunorubicin, Rubex, Filgrastim, Filgrastim Biosimilar Filgrastim-sndz, Filgrastim Biosimilar Tbo-filgrastim, Filgrastim XM02, Filgrastim-aafi, Filgrastim-ayow, Filgrastim-sndz, G-CSF, Granix, Neupogen, Neutroval, Nivestim, Nivestym, r-metHuG-CSF, Recombinant Methionyl Human Granulocyte Colony Stimulating Factor, Releuko, rG-CSF, Tbo-filgrastim, Tevagrastim, XM02, Zarxio, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Nivolumab, ABP 206, BCD-263, BMS 936558, BMS-936558, BMS936558, CMAB819, MDX 1106, MDX-1106, MDX1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO 4538, ONO-4538, ONO4538, Opdivo, Pegfilgrastim, Dulastin, Filgrastim SD-01, filgrastim-SD/01, Fulphila, Fylnetra, G-Lasta, HSP-130, Jinyouli, Neulasta, Neulastim, Neupopeg, Nyvepria, PEG-filgrastim, Pegcyte, Pegfilgrastim Biosimilar HSP-130, Pegfilgrastim Biosimilar Nyvepria, Pegfilgrastim Biosimilar Pegcyte, Pegfilgrastim Biosimilar PF-06881894, Pegfilgrastim Biosimilar Udenyca, Pegfilgrastim Biosimilar Ziextenzo, Pegfilgrastim-apgf, Pegfilgrastim-bmez, Pegfilgrastim-cbqv, Pegfilgrastim-fpgk, Pegfilgrastim-jmdb, Pegfilgrastim-pbbk, Pegylated G-CSF, Pegylated GCSF, Pegylated Granulocyte Colony Stimulating Factor, PF-06881894, SD-01, SD-01 sustained duration G-CSF, Stimufend, Tripegfilgrastim, Udenyca, Ziextenzo, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, PT, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Radiation Therapy, Cancer Radiotherapy, Energy Type, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation, Vinblastine Sulfate, 29060 LE, 29060-LE, Exal, Velban, Velbe, Velsar, VINCALEUKOBLASTINE
National Cancer Institute (NCI)
Ann Arbor Stage III Hodgkin Lymphoma, Ann Arbor Stage III Lymphocyte-Depleted Classic Hodgkin Lymphoma, Ann Arbor Stage III Mixed Cellularity Classic Hodgkin Lymphoma, Ann Arbor Stage III Nodular Sclerosis Classic Hodgkin Lymphoma, Ann Arbor Stage IV Hodgkin Lymphoma, Ann Arbor Stage IV Lymphocyte-Depleted Classic Hodgkin Lymphoma, Ann Arbor Stage IV Mixed Cellularity Classic Hodgkin Lymphoma, Ann Arbor Stage IV Nodular Sclerosis Classic Hodgkin Lymphoma, Classic Hodgkin Lymphoma, Lymphocyte-Rich Classic Hodgkin Lymphoma
03/24
03/26
NCT06520176: Comparison Study of EAP and CG Regimens for Mobilizing Hematopoietic Stem Cells in Multiple Myeloma Patients

Recruiting
3
99
RoW
Etoposide, VP-16, Cytarabine, Ara-C, Pegfilgrastim, PEG-rhG-CSF, Cyclophosphamide, Cy, G-CSF, Granulocyte Colony Stimulating Factor
The Affiliated People's Hospital of Ningbo University, First Affiliated Hospital of Zhejiang University, First Affiliated Hospital of Wenzhou Medical University, Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University, The Central Hospital of Lishui City, Jinhua People's Hospital, Shaoxing People's Hospital, Shaoxing Second Hospital, Zhejiang Provincial Tongde Hospital, Taizhou Hospital, Dongyang People's Hospital, Affiliated Hospital of Jiaxing University, Huizhou Municipal Central Hospital, Second Affiliated Hospital of Wenzhou Medical University, Ningbo Medical Center Lihuili Hospital, Jinhua Municipal Central Hospital
Multiple Myeloma, Hematopoietic Stem Cell Mobilization
12/26
12/26
NCT04759586: Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma

Active, not recruiting
3
244
Canada, US, RoW
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Asta B 518, B 518, B-518, B518, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR 138719, WR- 138719, WR-138719, WR138719, Doxorubicin Hydrochloride, 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI), ADM, Adriacin, Adriamycin, Adriamycin Hydrochloride, Adriamycin PFS, Adriamycin RDF, ADRIAMYCIN, HYDROCHLORIDE, Adriamycine, Adriblastina, Adriblastine, Adrimedac, Chloridrato de Doxorrubicina, DOX, DOXO-CELL, Doxolem, Doxorubicin HCl, Doxorubicin.HCl, Doxorubin, Farmiblastina, FI 106, FI-106, FI106, hydroxydaunorubicin, Rubex, Echocardiography Test, EC, Echocardiography, Etoposide Phosphate, Etopophos, Filgrastim, Filgrastim Biosimilar Filgrastim-sndz, Filgrastim Biosimilar Tbo-filgrastim, Filgrastim XM02, Filgrastim-aafi, Filgrastim-ayow, Filgrastim-sndz, G-CSF, Granix, Neupogen, Neutroval, Nivestim, Nivestym, r-metHuG-CSF, Recombinant Methionyl Human Granulocyte Colony Stimulating Factor, Releuko, rG-CSF, Tbo-filgrastim, Tevagrastim, XM02, Zarxio, Lumbar Puncture, LP, Spinal Tap, Nivolumab, ABP 206, BCD-263, BMS 936558, BMS-936558, BMS936558, CMAB819, MDX 1106, MDX-1106, MDX1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO 4538, ONO-4538, ONO4538, Opdivo, Pegfilgrastim, Dulastin, Filgrastim SD-01, filgrastim-SD/01, Fulphila, Fylnetra, G-Lasta, HSP-130, Jinyouli, Neulasta, Neulastim, Neupopeg, Nyvepria, PEG-filgrastim, Pegcyte, Pegfilgrastim Biosimilar HSP-130, Pegfilgrastim Biosimilar Nyvepria, Pegfilgrastim Biosimilar Pegcyte, Pegfilgrastim Biosimilar PF-06881894, Pegfilgrastim Biosimilar Udenyca, Pegfilgrastim Biosimilar Ziextenzo, Pegfilgrastim-apgf, Pegfilgrastim-bmez, Pegfilgrastim-cbqv, Pegfilgrastim-fpgk, Pegfilgrastim-jmdb, Pegfilgrastim-pbbk, Pegylated G-CSF, Pegylated GCSF, Pegylated Granulocyte Colony Stimulating Factor, PF-06881894, SD-01, SD-01 sustained duration G-CSF, Stimufend, Tripegfilgrastim, Udenyca, Ziextenzo, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, PT, Prednisolone, (11beta)-11,17,21-Trihydroxypregna-1,4-diene-3,20-dione, .delta.1-Hydrocortisone, Adnisolone, Aprednislon, Capsoid, Cortalone, Cortisolone, Dacortin H, Decaprednil, Decortin H, Delta(1)Hydrocortisone, Delta- Cortef, Delta-Cortef, Delta-Diona, Delta-F, Delta-Phoricol, Delta1-dehydro-hydrocortisone, Deltacortril, Deltahydrocortisone, Deltasolone, Deltidrosol, Dhasolone, Di-Adreson-F, Dontisolon D, Estilsona, Fisopred, Frisolona, Gupisone, Hostacortin H, Hydeltra, Hydeltrasol, Klismacort, Kuhlprednon, Lenisolone, Lepi-Cortinolo, Linola-H N, Linola-H-Fett N, Longiprednil, Metacortandralone, Meti Derm, Meticortelone, Opredsone, Panafcortelone, Precortisyl, Pred-Clysma, Predeltilone, Predni-Coelin, Predni-Helvacort, Prednicortelone, Prednisolonum, Prelone, Prenilone, Sterane, Prednisone, .delta.1-Cortisone, 1, 2-Dehydrocortisone, Adasone, Cortancyl, Dacortin, DeCortin, Decortisyl, Decorton, Delta 1-Cortisone, Delta-Dome, Deltacortene, Deltacortisone, Deltadehydrocortisone, Deltasone, Deltison, Deltra, Econosone, Lisacort, Meprosona-F, Metacortandracin, Meticorten, Ofisolona, Orasone, Panafcort, Panasol-S, Paracort, Perrigo Prednisone, PRED, Predicor, Predicorten, Prednicen-M, Prednicort, Prednidib, Prednilonga, Predniment, Prednisone Intensol, Prednisonum, Prednitone, Promifen, Rayos, Servisone, SK-Prednisone, Radiation Therapy, Cancer Radiotherapy, Energy Type, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation, Rituximab, ABP 798, ABP-798, ABP798, BI 695500, BI-695500, BI695500, Blitzima, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT P10, CT-P10, CTP10, GP 2013, GP-2013, GP2013, IDEC 102, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, IDEC102, Ikgdar, Mabtas, MabThera, Monoclonal Antibody IDEC-C2B8, PF 05280586, PF-05280586, PF05280586, Riabni, Ritemvia, Rituxan, Rituximab ABBS, Rituximab ARRX, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar GP2013, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, Rituximab Biosimilar SIBP-02, rituximab biosimilar TQB2303, Rituximab PVVR, Rituximab-abbs, Rituximab-arrx, Rituximab-blit, Rituximab-pvvr, Rituximab-rite, Rituximab-rixa, Rituximab-rixi, Rixathon, Riximyo, RTXM 83, RTXM-83, RTXM83, Ruxience, Truxima, Rituximab and Hyaluronidase Human, Rituxan Hycela, Rituximab Plus Hyaluronidase, Rituximab/Hyaluronidase, Rituximab/Hyaluronidase Human, Vincristine Sulfate, Kyocristine, Leurocristine Sulfate, Leurocristine, sulfate, Oncovin, Vincasar, Vincosid, Vincrex, Vincristine, sulfate
National Cancer Institute (NCI)
Primary Mediastinal Large B-Cell Lymphoma
12/27
12/27
NCT04628767: Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer

Recruiting
2/3
249
US
Biopsy Procedure, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Doxorubicin Hydrochloride, 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI), ADM, Adriacin, Adriamycin, Adriamycin Hydrochloride, Adriamycin PFS, Adriamycin RDF, ADRIAMYCIN, HYDROCHLORIDE, Adriamycine, Adriblastina, Adriblastine, Adrimedac, Chloridrato de Doxorrubicina, DOX, DOXO-CELL, Doxolem, Doxorubicin HCl, Doxorubicin.HCl, Doxorubin, Farmiblastina, FI 106, FI-106, FI106, hydroxydaunorubicin, Rubex, Durvalumab, Imfinzi, Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer, MEDI 4736, MEDI-4736, MEDI4736, Gemcitabine Hydrochloride, dFdCyd, Difluorodeoxycytidine Hydrochloride, Gemcitabine HCI, Gemzar, LY 188011, LY-188011, LY188011, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Methotrexate, Abitrexate, Alpha-Methopterin, Amethopterin, Brimexate, CL 14377, CL-14377, Emtexate, Emthexat, Emthexate, Farmitrexat, Fauldexato, Folex, Folex PFS, Jylamvo, Lantarel, Ledertrexate, Lumexon, Maxtrex, Medsatrexate, Metex, Methoblastin, Methotrexate LPF, Methotrexate Methylaminopterin, Methotrexatum, Metotrexato, Metrotex, Mexate, Mexate-AQ, MTX, Novatrex, Rheumatrex, Texate, Tremetex, Trexeron, Trixilem, WR-19039, Pegfilgrastim, Dulastin, Filgrastim SD-01, filgrastim-SD/01, Fulphila, Fylnetra, G-Lasta, HSP-130, Jinyouli, Neulasta, Neulastim, Neupopeg, Nyvepria, PEG-filgrastim, Pegcyte, Pegfilgrastim Biosimilar HSP-130, Pegfilgrastim Biosimilar Nyvepria, Pegfilgrastim Biosimilar Pegcyte, Pegfilgrastim Biosimilar PF-06881894, Pegfilgrastim Biosimilar Udenyca, Pegfilgrastim Biosimilar Ziextenzo, Pegfilgrastim-apgf, Pegfilgrastim-bmez, Pegfilgrastim-cbqv, Pegfilgrastim-fpgk, Pegfilgrastim-jmdb, Pegfilgrastim-pbbk, Pegylated G-CSF, Pegylated GCSF, Pegylated Granulocyte Colony Stimulating Factor, PF-06881894, SD-01, SD-01 sustained duration G-CSF, Stimufend, Tripegfilgrastim, Udenyca, Ziextenzo, Therapeutic Conventional Surgery, Vinblastine Sulfate, 29060 LE, 29060-LE, Exal, Velban, Velbe, Velsar, VINCALEUKOBLASTINE
National Cancer Institute (NCI)
Renal Pelvis and Ureter Urothelial Carcinoma
09/27
09/27
S0533, NCT00334815: Combination Chemotherapy, Radiation Therapy, and Bevacizumab in Treating Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery

Checkmark P1/2 data - ASCO/ASTRO/IASLC 2012
Sep 2012 - Sep 2012: P1/2 data - ASCO/ASTRO/IASLC 2012
Checkmark P1/2 data-ASCO
Jun 2012 - Jun 2012: P1/2 data-ASCO
Checkmark P2 data 1st line NSCLC
More
Active, not recruiting
2
29
US
Bevacizumab, ABP 215, ABP-215, ABP215, Alymsys, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF Monoclonal Antibody SIBP04, Anti-VEGF rhuMAb, Avastin, Avzivi, Aybintio, BAT 1706, BAT-1706, BAT1706, BAT1706 Biosimilar, Bevacizumab awwb, Bevacizumab Biosimilar ABP 215, Bevacizumab Biosimilar BAT1706, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Bevacizumab Biosimilar CBT 124, Bevacizumab Biosimilar CT-P16, Bevacizumab Biosimilar FKB238, Bevacizumab Biosimilar GB-222, Bevacizumab Biosimilar HD204, Bevacizumab Biosimilar HLX04, Bevacizumab Biosimilar IBI305, Bevacizumab Biosimilar LY01008, Bevacizumab Biosimilar MB02, Bevacizumab Biosimilar MIL60, Bevacizumab Biosimilar Mvasi, Bevacizumab Biosimilar MYL-1402O, Bevacizumab Biosimilar QL 1101, Bevacizumab Biosimilar QL1101, Bevacizumab Biosimilar RPH-001, Bevacizumab Biosimilar SCT501, Bevacizumab Biosimilar Zirabev, Bevacizumab-adcd, Bevacizumab-awwb, Bevacizumab-aybi, Bevacizumab-bvzr, Bevacizumab-equi, Bevacizumab-maly, Bevacizumab-onbe, Bevacizumab-tnjn, BP102, BP102 Biosimilar, CT P16, CT-P16, CTP16, Equidacent, FKB 238, FKB-238, FKB238, HD204, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, MB 02, MB-02, MB02, Mvasi, MYL-1402O, Onbevzi, Oyavas, PF 06439535, PF-06439535, PF06439535, QL1101, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, SCT501, SIBP 04, SIBP-04, SIBP04, Vegzelma, Zirabev, Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Docetaxel, Docecad, RP 56976, RP-56976, RP56976, Taxotere, Taxotere Injection Concentrate, Etoposide, Demethyl Epipodophyllotoxin Ethylidine Glucoside, EPEG, Lastet, Toposar, Vepesid, VP 16, VP 16-213, VP 16213, VP-16, VP-16-213, VP-16213, VP16, VP16213, Filgrastim, Filgrastim Biosimilar Filgrastim-sndz, Filgrastim Biosimilar Tbo-filgrastim, Filgrastim XM02, Filgrastim-aafi, Filgrastim-ayow, Filgrastim-sndz, G-CSF, Granix, Neupogen, Neutroval, Nivestim, Nivestym, r-metHuG-CSF, Recombinant Methionyl Human Granulocyte Colony Stimulating Factor, Releuko, rG-CSF, Tbo-filgrastim, Tevagrastim, XM02, Zarxio, Pegfilgrastim, Dulastin, Filgrastim SD-01, filgrastim-SD/01, Fulphila, Fylnetra, G-Lasta, HSP-130, Jinyouli, Neulasta, Neulastim, Neupopeg, Nyvepria, PEG-filgrastim, Pegcyte, Pegfilgrastim Biosimilar HSP-130, Pegfilgrastim Biosimilar Nyvepria, Pegfilgrastim Biosimilar Pegcyte, Pegfilgrastim Biosimilar PF-06881894, Pegfilgrastim Biosimilar Udenyca, Pegfilgrastim Biosimilar Ziextenzo, Pegfilgrastim-apgf, Pegfilgrastim-bmez, Pegfilgrastim-cbqv, Pegfilgrastim-fpgk, Pegfilgrastim-jmdb, Pegfilgrastim-pbbk, Pegylated G-CSF, Pegylated GCSF, Pegylated Granulocyte Colony Stimulating Factor, PF-06881894, SD-01, SD-01 sustained duration G-CSF, Stimufend, Tripegfilgrastim, Udenyca, Ziextenzo, Radiation Therapy, Cancer Radiotherapy, Energy Type, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation
National Cancer Institute (NCI)
Lung Adenocarcinoma, Lung Adenosquamous Carcinoma, Lung Large Cell Carcinoma, Lung Squamous Cell Carcinoma, Minimally Invasive Lung Adenocarcinoma, Stage IIIA Lung Non-Small Cell Cancer AJCC v7, Stage IIIB Lung Non-Small Cell Cancer AJCC v7
07/14
02/26
Dulastin, NCT06135896: Tripegfilgrastim Trial to Reduce the Risk of Severe Neutropenia in Patients With Unresectable Pancreaticobiliary Cancers

Recruiting
2
98
RoW
Tripegfilgrastim, Dulastin
National Cancer Center, Korea, Seoul National University Hospital
Unresectable Pancreatic Cancer, Unresectable Bile Duct Carcinoma, Unresectable Biliary Tract Carcinoma
06/26
06/26
NCT06738368: Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia

Not yet recruiting
2
30
US
Asparaginase Erwinia chrysanthemi, Asparaginase Erwinia chrysanthemi (Recombinant)-rywn, Asparaginase Erwinia chrysanthemi, Recombinant-rywn, Asparaginase Erwinia chrysanthemi-rywn, Crisantaspase, Crisantaspase Biobetter JZP-458, Crisantaspasum, Enrylaze, Erwinase, Erwinaze, JZP 458, JZP-458, JZP458, PF743, RC-P JZP-458, Recombinant Asparaginase erwinia chrysanthemi JZP-458, Recombinant Crisantaspase JZP-458, Recombinant Erwinia asparaginase JZP-458, Rylaze, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Collection, Collection, Bone Marrow, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Asta B 518, B 518, B-518, B518, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR 138719, WR- 138719, WR-138719, WR138719, Doxorubicin, Adriablastin, Hydroxydaunomycin, Hydroxyl Daunorubicin, Hydroxyldaunorubicin, Etoposide, Demethyl Epipodophyllotoxin Ethylidine Glucoside, EPEG, Lastet, Toposar, Vepesid, VP 16, VP 16-213, VP 16213, VP-16, VP-16-213, VP-16213, VP16, VP16213, Filgrastim, Filgrastim Biosimilar Filgrastim-sndz, Filgrastim Biosimilar Tbo-filgrastim, Filgrastim XM02, Filgrastim-aafi, Filgrastim-ayow, Filgrastim-sndz, G-CSF, Granix, Neupogen, Neutroval, Nivestim, Nivestym, r-metHuG-CSF, Recombinant Methionyl Human Granulocyte Colony Stimulating Factor, Releuko, rG-CSF, Tbo-filgrastim, Tevagrastim, XM02, Zarxio, Pegfilgrastim, Dulastin, Filgrastim SD-01, filgrastim-SD/01, Fulphila, Fylnetra, G-Lasta, HSP-130, Jinyouli, Neulasta, Neulastim, Neupopeg, Nyvepria, PEG-filgrastim, Pegcyte, Pegfilgrastim Biosimilar HSP-130, Pegfilgrastim Biosimilar Nyvepria, Pegfilgrastim Biosimilar Pegcyte, Pegfilgrastim Biosimilar PF-06881894, Pegfilgrastim Biosimilar Udenyca, Pegfilgrastim Biosimilar Ziextenzo, Pegfilgrastim-apgf, Pegfilgrastim-bmez, Pegfilgrastim-cbqv, Pegfilgrastim-fpgk, Pegfilgrastim-jmdb, Pegfilgrastim-pbbk, Pegylated G-CSF, Pegylated GCSF, Pegylated Granulocyte Colony Stimulating Factor, PF-06881894, SD-01, SD-01 sustained duration G-CSF, Stimufend, Tripegfilgrastim, Udenyca, Ziextenzo, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Prednisone, .delta.1-Cortisone, 1, 2-Dehydrocortisone, Adasone, Cortancyl, Dacortin, DeCortin, Decortisyl, Decorton, Delta 1-Cortisone, Delta-Dome, Deltacortene, Deltacortisone, Deltadehydrocortisone, Deltasone, Deltison, Deltra, Econosone, Lisacort, Meprosona-F, Metacortandracin, Meticorten, Ofisolona, Orasone, Panafcort, Panasol-S, Paracort, Perrigo Prednisone, PRED, Predicor, Predicorten, Prednicen-M, Prednicort, Prednidib, Prednilonga, Predniment, Prednisone Intensol, Prednisonum, Prednitone, Promifen, Rayos, Servisone, SK-Prednisone, Rituximab, ABP 798, BI 695500, BI-695500, BI695500, Blitzima, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC 102, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, IDEC102, Ikgdar, Mabtas, MabThera, Monoclonal Antibody IDEC-C2B8, PF 05280586, PF-05280586, PF05280586, Riabni, Ritemvia, Rituxan, Rituximab ABBS, Rituximab ARRX, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, Rituximab Biosimilar SIBP-02, rituximab biosimilar TQB2303, Rituximab PVVR, Rituximab-abbs, Rituximab-arrx, Rituximab-blit, Rituximab-pvvr, Rituximab-rite, Rituximab-rixa, Rituximab-rixi, Rixathon, Riximyo, RTXM 83, RTXM-83, RTXM83, Ruxience, Truxima, Vincristine, LCR, Leurocristine, VCR, Vincrystine
University of Washington, Jazz Pharmaceuticals
B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, T Acute Lymphoblastic Leukemia
12/27
06/28
NCT04684368: A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT

Recruiting
2
160
Canada, US, RoW
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, JM8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Etoposide, Demethyl Epipodophyllotoxin Ethylidine Glucoside, EPEG, Lastet, Toposar, Vepesid, VP 16, VP 16-213, VP 16213, VP-16, VP-16-213, VP16, Filgrastim, Filgrastim Biosimilar Filgrastim-sndz, Filgrastim Biosimilar Tbo-filgrastim, Filgrastim XM02, Filgrastim-aafi, Filgrastim-ayow, Filgrastim-sndz, G-CSF, Granix, Neupogen, Neutroval, Nivestym, r-metHuG-CSF, Recombinant Methionyl Human Granulocyte Colony Stimulating Factor, Releuko, rG-CSF, Tbo-filgrastim, Tevagrastim, XM02, Zarxio, Ifosfamide, Asta Z 4942, Asta Z-4942, Cyfos, Holoxan, Holoxane, Ifex, IFO, IFO-Cell, Ifolem, Ifomida, Ifomide, Ifosfamidum, Ifoxan, IFX, Iphosphamid, Iphosphamide, Iso-Endoxan, Isoendoxan, Isophosphamide, Mitoxana, MJF 9325, MJF-9325, Naxamide, Seromida, Tronoxal, Z 4942, Z-4942, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Mesna, 2-Mercaptoethanesulfonate, Sodium Salt, Ausobronc, D-7093, Filesna, Mercaptoethane Sulfonate, Mercaptoethanesulfonate, Mesnex, Mesnil, Mesnum, Mexan, Mistabron, Mistabronco, Mitexan, Mucofluid, Mucolene, UCB 3983, Uromitexan, Ziken, Pegfilgrastim, Dulastin, Filgrastim SD-01, filgrastim-SD/01, Fulphila, HSP-130, Jinyouli, Neulasta, Neulastim, Neupopeg, Nyvepria, PEG-filgrastim, Pegcyte, Pegfilgrastim Biosimilar HSP-130, Pegfilgrastim Biosimilar Nyvepria, Pegfilgrastim Biosimilar Pegcyte, Pegfilgrastim Biosimilar PF-06881894, Pegfilgrastim Biosimilar Udenyca, Pegfilgrastim Biosimilar Ziextenzo, Pegfilgrastim-apgf, Pegfilgrastim-bmez, Pegfilgrastim-cbqv, Pegfilgrastim-jmdb, Pegylated G-CSF, Pegylated GCSF, Pegylated Granulocyte Colony Stimulating Factor, PF-06881894, SD-01, SD-01 sustained duration G-CSF, Tripegfilgrastim, Udenyca, Ziextenzo, Peripheral Blood Stem Cell Transplantation, PBPC transplantation, PBSCT, Peripheral Blood, Peripheral Blood Progenitor Cell Transplantation, PERIPHERAL BLOOD STEM CELL TRANSPLANT, Peripheral Stem Cell Support, Peripheral Stem Cell Transplant, Peripheral Stem Cell Transplantation, Questionnaire Administration, Radiation Therapy, Cancer Radiotherapy, Energy Type, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation, Second-Look Surgery, Reoperation, Repeat Surgery, Second Look, Surgical Revision, Thiotepa, 1,1',1''-Phosphinothioylidynetrisaziridine, Girostan, N,N', N''-Triethylenethiophosphoramide, Oncotiotepa, STEPA, Tepadina, TESPA, Tespamin, Tespamine, Thio-Tepa, Thiofosfamide, Thiofozil, Thiophosphamide, Thiophosphoamide, Thiophosphoramide, Thiotef, Tifosyl, TIO TEF, Tio-tef, Triethylene Thiophosphoramide, Triethylenethiophosphoramide, Tris(1-aziridinyl)phosphine sulfide, TSPA, WR 45312
Children's Oncology Group, National Cancer Institute (NCI)
Central Nervous System Nongerminomatous Germ Cell Tumor, Choriocarcinoma, Embryonal Carcinoma, Immature Teratoma, Malignant Teratoma, Mixed Germ Cell Tumor, Pineal Region Germ Cell Tumor, Pineal Region Immature Teratoma, Pineal Region Yolk Sac Tumor, Suprasellar Germ Cell Tumor
12/29
12/29
NCT03220022: Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell Lymphomas

Active, not recruiting
1
54
US
Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Asta B 518, B 518, B-518, B518, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR 138719, WR- 138719, WR-138719, WR138719, Doxorubicin Hydrochloride, 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI), ADM, Adriacin, Adriamycin, Adriamycin Hydrochloride, Adriamycin PFS, Adriamycin RDF, ADRIAMYCIN, HYDROCHLORIDE, Adriamycine, Adriblastina, Adriblastine, Adrimedac, Chloridrato de Doxorrubicina, DOX, DOXO-CELL, Doxolem, Doxorubicin HCl, Doxorubicin.HCl, Doxorubin, Farmiblastina, FI 106, FI-106, FI106, hydroxydaunorubicin, Rubex, Etoposide, Demethyl Epipodophyllotoxin Ethylidine Glucoside, EPEG, Lastet, Toposar, Vepesid, VP 16, VP 16-213, VP 16213, VP-16, VP-16-213, VP-16213, VP16, VP16213, Filgrastim, Filgrastim Biosimilar Filgrastim-sndz, Filgrastim Biosimilar Tbo-filgrastim, Filgrastim XM02, Filgrastim-aafi, Filgrastim-ayow, Filgrastim-sndz, G-CSF, Granix, Neupogen, Neutroval, Nivestim, Nivestym, r-metHuG-CSF, Recombinant Methionyl Human Granulocyte Colony Stimulating Factor, Releuko, rG-CSF, Tbo-filgrastim, Tevagrastim, XM02, Zarxio, Ibrutinib, BTK Inhibitor PCI-32765, CRA 032765, CRA-032765, CRA032765, Imbruvica, PCI 32765, PCI-32765, PCI32765, Laboratory Biomarker Analysis, Pegfilgrastim, Dulastin, Filgrastim SD-01, filgrastim-SD/01, Fulphila, Fylnetra, G-Lasta, HSP-130, Jinyouli, Neulasta, Neulastim, Neupopeg, Nyvepria, PEG-filgrastim, Pegcyte, Pegfilgrastim Biosimilar HSP-130, Pegfilgrastim Biosimilar Nyvepria, Pegfilgrastim Biosimilar Pegcyte, Pegfilgrastim Biosimilar PF-06881894, Pegfilgrastim Biosimilar Udenyca, Pegfilgrastim Biosimilar Ziextenzo, Pegfilgrastim-apgf, Pegfilgrastim-bmez, Pegfilgrastim-cbqv, Pegfilgrastim-fpgk, Pegfilgrastim-jmdb, Pegfilgrastim-pbbk, Pegylated G-CSF, Pegylated GCSF, Pegylated Granulocyte Colony Stimulating Factor, PF-06881894, SD-01, SD-01 sustained duration G-CSF, Stimufend, Tripegfilgrastim, Udenyca, Ziextenzo, Pharmacological Study, Prednisone, .delta.1-Cortisone, 1, 2-Dehydrocortisone, Adasone, Cortancyl, Dacortin, DeCortin, Decortisyl, Decorton, Delta 1-Cortisone, Delta-Dome, Deltacortene, Deltacortisone, Deltadehydrocortisone, Deltasone, Deltison, Deltra, Econosone, Lisacort, Meprosona-F, Metacortandracin, Meticorten, Ofisolona, Orasone, Panafcort, Panasol-S, Paracort, Perrigo Prednisone, PRED, Predicor, Predicorten, Prednicen-M, Prednicort, Prednidib, Prednilonga, Predniment, Prednisone Intensol, Prednisonum, Prednitone, Promifen, Rayos, Servisone, SK-Prednisone, Rituximab, ABP 798, ABP-798, ABP798, BI 695500, BI-695500, BI695500, Blitzima, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT P10, CT-P10, CTP10, GP 2013, GP-2013, GP2013, IDEC 102, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, IDEC102, Ikgdar, Mabtas, MabThera, Monoclonal Antibody IDEC-C2B8, PF 05280586, PF-05280586, PF05280586, Riabni, Ritemvia, Rituxan, Rituximab ABBS, Rituximab ARRX, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar GP2013, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, Rituximab Biosimilar SIBP-02, rituximab biosimilar TQB2303, Rituximab PVVR, Rituximab-abbs, Rituximab-arrx, Rituximab-blit, Rituximab-pvvr, Rituximab-rite, Rituximab-rixa, Rituximab-rixi, Rixathon, Riximyo, RTXM 83, RTXM-83, RTXM83, Ruxience, Truxima, Vincristine Sulfate, Kyocristine, Leurocristine Sulfate, Leurocristine, sulfate, Oncovin, Vincasar, Vincosid, Vincrex, Vincristine, sulfate
National Cancer Institute (NCI)
AIDS-Related Lymphoma, Ann Arbor Stage II Diffuse Large B-Cell Lymphoma, Ann Arbor Stage III Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma
07/25
07/25
recoflavone (DA-6034) / GL PharmTech, AJU Pharm
NCT06291194: Efficacy and Safety of AJU-S56 5% in Dry Eye Syndrome Patients

Recruiting
3
396
RoW
AJU-S56 5%, Test Group, Placebo Group(Vehicle), Control Group
AJU Pharm Co., Ltd., GL Pharm Tech Corporation
Dry Eye Syndromes
05/24
05/24
NCT06337981: Efficacy and Safety of AJU-S56 in Dry Eye Syndrome Patients

Completed
2
99
RoW
(AJU-S56 5% and placebo), Test 1 group(AJU-S56 5% and placebo, each 1 drop/1time, 3times in a day), AJU-S56 5%, Test 2 group(AJU-S56 5%, 1 drop/1time, 6times in a day), Placebo(Vehicle), Placebo group(Vehicle, 1 drop/1time, 6times in a day)
AJU Pharm Co., Ltd., GL Pharm Tech Corporation
Dry Eye Syndromes
06/22
11/22
GLH8NDE-201, NCT04679883: Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of GLH8NDE in Patients With Dry Eye Disease

Not yet recruiting
2
99
RoW
5% GLH8NDE, Placebo
GL Pharm Tech Corporation
Dry Eye Syndromes
01/22
04/22
cenicriviroc (TBR-652) / Takeda, AbbVie
2015-002955-85: A phase II feasibility study to assess changes in patients who have been identified as having cognitive function impairment following the addition of a new drug to an existing effective regime of three HIV antiretrovirals drugs

Ongoing
2
10
Europe
Cenicriviroc, TBR-652, Tablet
Imperial College London, Imperial College Healthcare NHS Trust Biomedical Research Centre
Human Immunodeficiency Virus, HIV, Diseases [C] - Virus Diseases [C02]
 
 
I-SPY_COVID, NCT04488081: I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients

Recruiting
2
1500
US
Remdesivir, GS-5734, Imatinib Mesylate, Dexamethasone, Cenicriviroc, Icatibant, Firazyr, Apremilast, Otezla, dornase alfa, Pulmozyme, Celecoxib, celebrex, Famotidine, Pepcid, IC14, Aviptadil, Zyesami, narsoplimab, OMS721, Cyproheptadine, periactin, Cyclosporine, CsA
QuantumLeap Healthcare Collaborative, University of California, San Francisco, University of Pennsylvania, Emory University, University of Alabama at Birmingham, University of Colorado, Denver, University of Southern California, Yale University, Wake Forest University Health Sciences, Sanford Health, Long Beach Memorial Medical Center, Georgetown University, University of California, Davis, Hoag Memorial Hospital Presbyterian, Main Line Health, DHR Health Institute for Research and Development, University of California, Irvine, Corewell Health, Kaiser Permanente, University of Michigan, West Virginia University, University of Miami, University Hospitals Cleveland Medical Center, Virtua Health, M.D. Anderson Cancer Center
COVID-19
07/28
07/30
NCT05630885: A Study to Evaluate the Effects of Cenicriviroc Mesylate on Arterial Inflammation in People Living With HIV

Completed
2
110
US
CVC 150 mg, CVC 300 mg, Placebo for CVC 150 mg, Placebo for CVC 300 mg
National Institute of Allergy and Infectious Diseases (NIAID), AbbVie
HIV-1-infection
06/24
06/24
basroparib (STP1002) / Dong-A
NCT04505839: First-In-Human Dose-Escalation Study of STP1002 in Patients With Advanced-Stage Solid Tumors

Completed
1
32
US
STP1002, Basroparib
ST Pharm Co., Ltd., KCRN Research, LLC
Advanced Solid Tumor
03/23
03/23
Branigen (acetyl-L-carnitine) / Mitsubishi Tanabe, Dong-A, Leadiant Biosci
2011-006235-33: Comparison of two products (dextrorotatory enantiomer of thioctic acid - food supplement - and acetyl-l-carnitine - drug) in the treatment of sciatic nerve disease Confronto dell'azione di due prodotti (enantiomero destrogiro dell'acido tioctico - integratore alimentare - e acetil-l-carnitina - specialita' medicinale) nel trattamento delle sofferenze del nervo sciatico

Ongoing
4
100
Europe
THIOCTIC ACID, NA, Gastro-resistant tablet, Tablet, NICETILE*30CPR 500MG
MDM S.P.A., MDM S.p.A.
sensitive motor sciatic neuropathy neuropatie sensitivo motorie del nervo sciatico, sciatic nerve disease sofferenza del nervo sciatico, Diseases [C] - Nervous System Diseases [C10]
 
 
Sugamet SR (evogliptin/metformin) / Dong-A
NCT05739877: Phamacokinetics and Safety Profiles of DA-1229_01 2.5/500mg in Healthy Subjects at Fed State

Not yet recruiting
1
34
RoW
DA-1229_01 2.5/500mg (Before), DA-1229_01 2.5/500mg (After)
Dong-A ST Co., Ltd.
Healthy
04/23
04/23
NCT05739851: Phamacokinetics and Safety Profiles of DA-1229_01 2.5/500mg in Healthy Subjects at Fasting State

Not yet recruiting
1
40
RoW
DA-1229_01 2.5/500mg (Before), DA-1229_01 2.5/500mg (After)
Dong-A ST Co., Ltd.
Healthy
04/23
04/23
NCT05739903: Phamacokinetics and Safety Profiles of DA-1229_01 5/1000mg in Healthy Subjects at Fasting State

Not yet recruiting
1
40
RoW
DA-1229_01 5/1000mg (Before), DA-1229_01 5/1000mg (After)
Dong-A ST Co., Ltd.
Healthy
04/23
04/23
NCT05739916: Phamacokinetics and Safety Profiles of DA-1229_01 5/1000mg in Healthy Subjects at Fed State

Not yet recruiting
1
34
RoW
DA-1229_01 5/1000mg (Before), DA-1229_01 5/1000mg (After)
Dong-A ST Co., Ltd.
Healthy
04/23
04/23
DA-1241 / Dong-A
DA1241_NASH_IIa, NCT06054815: Study to Evaluate the Efficacy and Safety of DA-1241 in Subjects With Presumed NASH

Completed
2
109
US
DA-1241, Sitagliptin, DA-1241 Placebo, Sitagliptin Placebo
NeuroBo Pharmaceuticals Inc.
NON-ALCOHOLIC STEATOHEPATITIS
10/24
10/24
donepezil transdermal patch (DA-5207) / Dong-A
NCT04479865: Phase 1 Clinical Trial to Evaluate the Safety, PK and PD of DA-5207 TDS in Healthy Adults

Active, not recruiting
1
49
RoW
Aricept 5mg Tablet, Aricept 10mg Tablet, DA-5207 150mg, DA-5207 170mg
Dong-A ST Co., Ltd.
Healthy
12/20
04/21
NCT05127746: Phase 1 Clinical Trial of DA-5207 in Healthy Adults

Completed
1
51
RoW
Aricept 5mg Tablet, Aricept 10mg Tablet, DA-5207 A, DA-5207 B
Dong-A ST Co., Ltd.
Healthy
12/22
12/22
retlirafusp alfa (SHR-1701) / Jiangsu Hengrui Pharma
SHR-1701-III-309, NCT05179239: A Study of SHR-1701 Plus Platinum-containing Chemotherapy With or Without BP102 (Bevacizumab) as First-line Treatment in Cervical Cancer

Terminated
3
31
RoW
SHR-1701 + paclitaxel + cisplatin/carboplatin + BP102, SHR-1701 + paclitaxel + cisplatin/carboplatin± BP102, Placebo + paclitaxel + cisplatin/carboplatin ± BP102
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Cervical Cancer
08/24
08/24
SHR-1701-III-310, NCT05132413: A Study of SHR-1701 Plus Bevacizumab and Chemotherapy in Non-Small-Cell-Lung-Cancer

Not yet recruiting
3
561
NA
SHR-1701 + Pemetrexed Disodium + cisplatin/carboplatin + bevacizumab, Placebo + SHR-1701 + Pemetrexed Disodium+ cisplatin/carboplatin, Placebo 1 + Placebo 2 +Pemetrexed Disodium + cisplatin/carboplatin
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Advanced or Metastatic Non-squamous Non-small-cell Lung Cancer
12/24
12/24
SHR-1701-III-307, NCT04950322: A Trial of SHR1701 Plus Chemotherapy in Patients With Gastric or Gastroesophageal Cancer

Active, not recruiting
3
737
RoW
SHR-1701、CAPOX, Placebo、CAPOX
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Gastric or Gastroesophageal Junction Cancer
05/24
10/25
SHR-1701-III-301, NCT04856787: A Clinical Studyf of SHR-1701 or Placebo in Combination With BP102 and XELOX in the First-line Treatment of mCRC

Terminated
2/3
62
RoW
SHR-1701、 BP102 、XELOX, placebo、 BP102、 XELOX
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Metastatic Colorectal Cancer (mCRC)
04/24
04/24
SHR-1701-III-308, NCT05149807: Clinical Study of SHR-1701 Plus Chemotherapy as Perioperative Treatment in Subjects With Gastric Cancer

Terminated
2/3
81
RoW
SHR-1701 injection, Placebo
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Perioperative Treatment in Subjects With Locally Advanced Resectable Gastric Cancer or Gastroesophageal Junction Cancer
04/24
04/24
SHR-1701-Ⅱ-206, NCT04699968: A Trial of SHR-1701 With or Without Famitinib in Patients With Advanced or Metastatic NSCLC

Withdrawn
2
168
NA
SHR-1701，Famitinib, SHR-1701
Jiangsu HengRui Medicine Co., Ltd.
Non-Small-Cell Lung Cancer
11/21
11/21
SHR-1701-II-207-LC, NCT04974957: Study of SHR-1701 Plus BP102 in Subjects With Selected Solid Tumors

Not yet recruiting
2
71
NA
SHR-1701；BP102
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer
02/22
08/22
NCT04560244: A Trial of SHR1701 Combined With Radiotherapy for Metastatic Non-small Cell Lung Cancer Failure After First-line Treatment

Not yet recruiting
2
15
NA
SHR1701
Shandong Cancer Hospital and Institute
Non-Small-Cell Lung Cancer
09/22
12/22
SHR-1701-II-209, NCT04884009: A Trial of SHR-1701 in Combination With and Without Famitinib Malate in Patients With Extensive Stage Small Cell Lung Cancer

Not yet recruiting
2
106
NA
SHR-1701； Famitinib, SHR-1701
Jiangsu HengRui Medicine Co., Ltd.
Lung Cancer
12/22
12/22
SHR-1701-II-208, NCT04650633: SHR-1701 in Patients With Recurrent/Metastatic Scchn

Recruiting
2
130
RoW
SHR-1701
Jiangsu HengRui Medicine Co., Ltd.
Squamous Cell Carcinoma of Head and Neck
01/23
01/23
MULAN, NCT04355858: Molecularly Targeted Umbrella Study in Luminal Advanced Breast Cancer

Recruiting
2
319
RoW
SHR7390, Famitinib, SHR3162, Pyrotinib, Capecitabine, SHR1210, Everolimus, Nab paclitaxel, SHR2554, SHR3680, SHR6390, SHR1701, SERD, AI, VEGFi
Fudan University
Breast Cancer, Metastatic Cancer
05/23
04/25
TRAILBLAZER, NCT04580498: A Trial of SHR-1701 With or Without Chemotherapy in Patients With Stage III NSCLC

Active, not recruiting
2
107
RoW
SHR-1701+Paclitaxel+carboplatin, SHR-1701
Jiangsu HengRui Medicine Co., Ltd.
Non-Small-Cell Lung Cancer
07/23
03/25
NCT05106023: To Explore the Efficacy and Safety of SHR-1701 Combined With Temozolomide in the Treatment of Advanced Melanoma

Recruiting
2
31
RoW
SHR-1701, SHR1701, Temozolomide
Yong Chen
Melanoma
09/23
12/23
FLYFLY, NCT04937972: SHR-1701 Combined With Fluzoparib in Lung Squamous Cell Carcinoma

Recruiting
2
71
RoW
SHR-1701 Combined With Fluazopalil
Hunan Province Tumor Hospital
Non-Small Cell Lung Cancer
12/24
06/25
NCT05177497: SHR-1701 for Consolidation Therapy After Concurrent Chemoradiotherapy in Inoperable Stage III NSCLC

Not yet recruiting
2
19
NA
SHR-1701
Shanghai Chest Hospital
NSCLC, Stage III
07/24
10/24
SHR-1701-II-213, NCT05300269: SHR-1701 in Combination With Chemotherapy and Radiotherapy in Locally Advanced Rectal Cancer

Recruiting
2
73
RoW
SHR-1701；Capecitabine；Oxaliplatin
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Locally Advanced Rectal Cancer
07/24
10/26
NCT06679673: SHR-1701 Combined with SHR2554 and BP102 for MCRC

Not yet recruiting
2
20
RoW
SHR-1701, BP102, SHR2554
Fudan University
Colorectal Cancer Metastatic
12/25
12/26
MA-GC-II-023, NCT06881017: Establishment of Precision Targeted Therapy Strategies for Advanced Gastric Cancer Based on Novel Molecular Subtyping

Not yet recruiting
2
140
NA
Trastuzumab, Adebrelimab, Apatinib, S-1, Capecitabine, Oxaliplatin, zolbetuximab, SHR-A1811, SHR-A1904, SHR-1701
China Medical University, China
Gastric Cancer, HER2 + Gastric Cancer, CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction, PD-L1 Positive
08/29
11/29
ChiCTR2300070675: SHR-1701 in combination with albumin paclitaxel and carboplatin for advanced head and neck squamous cell carcinoma

Not yet recruiting
2
43
 
SHR-1701, albumin paclitaxel, and carboplatin
Fudan University Shanghai Cancer Center; Fudan University Shanghai Cancer Center, Expenditure of department
Head and neck squamous cell carcinoma
 
 
SHR-A1811-Ib/II-205, NCT05671822: Ph1b/2 Study of the Safety and Efficacy of SHR-A1811 Combinations in Advanced HER2 Expression Gastric Cancer

Active, not recruiting
2
76
RoW
SHR-A1811 and SHR-1701, SHR-A1811 and capecitabine, SHR-A181, SHR-1701, and capecitabine, SHR-A1811, SHR-1316, and capecitabine, SHR-A1811, SHR-1316, capecitabine,and oxaliplatin, SHR-A1811, SHR-1316, and 5-FU, SHR-1316 and SHR-A1811, SHR-A1811and 5-FU
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
HER2 Expression Gastric Cancer/Gastroesophageal Junction Adenocarcinoma
04/25
07/26
SHR-1701-II-204, NCT04624217: A Trial of SHR-1701 in Combination With Gemcitabine and Albumin Paclitaxel in Patients With Pancreatic Cancer

Completed
1/2
56
RoW
SHR-1701, Gemcitabine and Albumin Paclitaxel
Jiangsu HengRui Medicine Co., Ltd.
Pancreatic Cancer
09/21
02/23
SHR-1701-II-207, NCT04856774: Trial of SHR-1701 Plus BP102 in Subjects With Selected Solid Tumors

Completed
1/2
81
RoW
SHR-1701；BP102
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Advanced Solid Tumors
03/24
03/24
SHR-1701-II-203-NPC, NCT05020925: SHR-1701 in Combination With Famitinib in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma

Not yet recruiting
1/2
30
RoW
SHR-1701, SHR-1701 Injection, Famitinib, SHR-1020
Jiangsu HengRui Medicine Co., Ltd.
Nasopharyngeal Carcinoma
05/22
02/24
SHR-1701-II-203, NCT04679038: A Trial of SHR-1701 in Combination With Famitinib in Patients With Advanced Solid Tumors

Recruiting
1/2
222
RoW
SHR-1701, Famitinib
Jiangsu HengRui Medicine Co., Ltd.
Solid Tumor
12/22
10/23
NCT04407741: Phase Ⅰ/Ⅱ Study of SHR2554 in Combination With SHR1701 in Patients With Advanced Solid Tumors and B-cell Lymphomas

Recruiting
1/2
100
RoW
SHR2554+SHR1701, SHR1701
Chinese PLA General Hospital
Solid Tumor, Lymphoma
12/24
12/25
NCT05896046: SHR1701 Alone or in Combination With SHR2554 in Relapsed or Refractory Classical Hodgkin Lymphoma

Recruiting
1/2
100
RoW
SHR2554+ SHR1701, SHR-1701
Chinese PLA General Hospital
Relapsed or Refractory Hodgkin Lymphoma
06/25
06/26
SHR-1701-215, NCT05503888: Phase Ib/II Study of Almonertinib Combined With SHR-1701 in the Treatment of Relapsed or Advanced Non-small Cell Lung Cancer

Not yet recruiting
1/2
160
NA
Almonertinib combined with SHR-1701, Almonertinib
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Relapsed or Advanced Non-small Cell Lung Cancer
07/27
07/27
SHR-1701-I-103, NCT04282070: SHR-1701 in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma

Active, not recruiting
1
91
RoW
SHR-1701, SHR-1701 Injection, Gemcitabine, Gemcitabine Hydrochloride for Injection, Cisplatin, Cisplatin Injection, Albumin Paclitaxel, nab-Paclitaxel
Jiangsu HengRui Medicine Co., Ltd.
Nasopharyngeal Carcinoma
04/22
12/22
SHR-1701-I-101, NCT03710265: SHR-1701 in Metastatic or Locally Advanced Solid Tumors

Recruiting
1
206
RoW
SHR-1701
Jiangsu HengRui Medicine Co., Ltd.
Solid Tumor
12/22
12/22
NCT05198817: A Trial of SHR-2002 Injection or Combined With Other Anti-cancer Medication in Advanced Malignant Tumors of Patients

Enrolling by invitation
1
240
RoW
SHR-2002 injection、Camrelizumab for Injection, SHR-1316 injection, SHR-1701 injection
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Advanced Malignant Tumors
01/23
06/23
SHR-1701-001AUS, NCT04324814: A Trial of SHR-1701 in Subjects With Advanced Solid Tumors

Completed
1
41
RoW
SHR-1701
Atridia Pty Ltd.
Advanced Solid Tumor
02/23
02/23
SHR-1701-I-102, NCT03774979: SHR-1701 in Subjects With Metastatic or Locally Advanced Solid Tumors

Active, not recruiting
1
193
RoW
SHR-1701
Jiangsu HengRui Medicine Co., Ltd.
Solid Tumor
03/23
12/23
NCT05048134: A Phase I Study of HRS2300 or Combined With SHR-1316 or SHR-1701 or Trametinib or Almonertinib in Patients With Advanced Malignancies

Terminated
1
13
RoW
HRS2300, HRS2300、 SHR-1316, HRS2300、SHR-1701, HRS2300、trametinib, HRS2300、Almonertinib
Jiangsu HengRui Medicine Co., Ltd.
Advanced Malignancies
02/23
05/23
ChiCTR2000037927: An exploratory study of SHR-1701 in combination with Famitinib in patients with Advanced Pancreatic cancer and Biliary Tract Cancer

Recruiting
N/A
60
 
SHR-1701 + Famitinib
Fudan University Shanghai Cancer Center; Fudan University Shanghai Cancer Center, The research drug was provided by Hengrui Pharmaceutical
Pancreatic cancer and Biliary Tract Cancer
 
 
ChiCTR2100046099: Clinical trial of an umbrella study of precise treatment of bone and soft tissue sarcoma based on molecular pathways

Recruiting
N/A
51
 
SHR-1701+Famitinib ;Camrelizumab+SHR-6390 ;SHR-2554
Affiliated Sixth People's Hospital, Shanghai Jiaotong University; Affiliated Sixth People's Hospital, Shanghai Jiaotong University, self-funded
advanced bone and soft tissue sarcoma
 
 
ChiCTR2000037146: A multicenter, randomized controlled trial of SHR1701 combined with GEMOX in treatment of biliary malignant tumor

Not yet recruiting
N/A
169
 
SHR1701 combined with GEMOX ;GEMOX
Renji Hospital, Shanghai Jiaotong University School of Medicine; Renji Hospital, Shanghai Jiaotong University School of Medicine, self-financing
biliary tract carcinoma
 
 
ChiCTR2000036960: Multicenter clinical study on precision treatment of biliary tract carcinoma

Not yet recruiting
N/A
76
 
SHR1701 combined with GEMOX
Renji Hospital, Shanghai Jiaotong University School of Medicine; Renji Hospital, Shanghai Jiaotong University School of Medicine, self-financing
biliary tract carcinoma
 
 
ChiCTR2300072634: SHR1701 in combination with Surufatinib as late-line treatment in advanced colorectal cancer

Not yet recruiting
N/A
38
 
SHR1701 and Surufatinib ;SHR1701 and Surufatinib
Shanghai East Hospital; Shanghai East Hospital, Fund
colorectal cancer
 
 
ICT-HCC, NCT06893887: Individualized Comprehensive Treatment for Advanced Hepatocellular Carcinoma

Recruiting
N/A
300
RoW
FOLFOX4, Adebrelimab, Apatinib, Icaritin, SHR-1701, QL1706, Bevacizumab, HAIC, Local treatment, The original treatment regimen
Nanjing Tianyinshan Hospital
Hepatocellular Carcinoma(HCC)
03/27
03/28
ChiCTR2200062197: A Phase II clinical study of SHR-1701 combined with albumin paclitaxel and carboplatin in the treatment of advanced non-small cell lung cancer with malignant pleural effusion

Not yet recruiting
N/A
42
 
SHR-1701 combined with albumin paclitaxel and carboplatin
West China Hospital of Sichuan University; West China Hospital of Sichuan University, Research Fund From Hospital
Non-small cell lung cancer with malignant pleural effusion
 
 
niclosamide (ANA001) / Dong-A
NCT04603924: Study of Niclosamide in Moderate and Severe Hospitalized Coronavirus-19 (COVID-19) Patients

Completed
2/3
49
US
Niclosamide, ANA001, Placebo, Matching Placebo to ANA001
NeuroBo Pharmaceuticals Inc.
COVID-19
02/22
02/22
NCT04705415: A Single and Multiple Ascending Dose Study of Niclosamide in Healthy Volunteers

Completed
1
54
US
Niclosamide, ANA001, Placebo, Matching Placebo to ANA001
NeuroBo Pharmaceuticals Inc.
Healthy
10/21
10/22
NCT05188170: Niclosamide in Pediatric Patients With Relapsed and Refractory AML

Recruiting
1
16
US
Niclosamide
Stanford University
Acute Myeloid Leukemia (AML)
07/25
12/26
DA8010 / Dong-A
NCT05282069: A Study to Evaluate the Efficacy and Safety of DA-8010 in Patients With Overactive Bladder

Completed
3
607
RoW
DA-8010 Placebo, DA-8010 2.5mg, DA-8010 5mg, Solifenacin 5mg, Solifenacin succinate placebo
Dong-A ST Co., Ltd.
Overactive Bladder
11/23
05/24
NCT05992428: Drug Interactions When DA-8010 is Co-administered With Paroxetine or Mirabegron in Healthy Adults

Completed
1
37
RoW
DA-8010 5mg, Paroxetine 20mg, Mirabegron 50mg
Dong-A ST Co., Ltd.
Healthy
11/23
12/23
NCT05991401: Evaluate the Effect of Clarithromycin/Rifampicin on the Pharmacokinetics of DA-8010 in Healthy Adults

Completed
1
18
RoW
DA-8010 5mg, Clarithromycin 500mg, Rifampicin 600mg
Dong-A ST Co., Ltd.
Healthy
11/23
11/23
NCT05812417: A Study to Evaluate the Effects of Renal Function on Pharmacokinetics and Safety of DA-8010

Completed
1
33
RoW
DA-8010
Dong-A ST Co., Ltd.
Renal Impairment, Healthy
06/24
06/24
DA-2811 / Dong-A
NCT05743907: Clinical Trial to Evaluate the Efficacy and Safety of DA-2811 When Added to Ongoing Metformin Monotherapy in Patients with Type 2 Diabetes Who Have Inadequate Glycemic Control

Completed
4
231
RoW
DA-2811, Forxiga
Dong-A ST Co., Ltd.
Diabetes Mellitus
03/25
03/25
DA-4507 / Dong-A
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Sugarnon (evogliptin) / Dong-A
EVOMETA, NCT04706637: A Clinical Trial to Evaluate the Bone Metabolism and the Blood Sugar of Evogliptin and Dapagliflozin

Not yet recruiting
4
120
RoW
Evogliptin, Dapagliflozin
Kyung Hee University Hospital at Gangdong, Dong-A ST Co., Ltd.
Bone Diseases, Metabolic, Diabetes Mellitus, Type 2
01/22
01/23
NCT04584242: Clinical Trials to Compare the Effects of Pioglitazone and Evogliptin on Hepatic Fibrosis in Patients With Chronic Hepatitis B With Significant Hepatic Fibrosis With Type 2 Diabetes

Recruiting
4
40
RoW
gluconon tab 15mg, suganon tab 5mg
Yonsei University
Chronic Hepatitis B With Significant Hepatic Fibrosis With Type 2 Diabetes
05/22
05/22
NCT05473806: Effects of Pioglitazone and Evogliptin on Hepatic Fibrosis in Patients With Chronic Hepatitis B With Type 2 Diabetes

Active, not recruiting
4
28
RoW
Pioglitazone 15 Mg Oral Tablet, Gluconon tablet 15mg, Evogliptin 5mg, SUGANON tablet 5mg
Seung Up Kim
Hepatitis B, Chronic, Fibrosis, Liver, Diabetes Mellitus, Type 2
01/23
02/23
NCT04521452: Randomized, Open-label Trial of Inhibitory Effect of Evogliptin on Progression of CAVD

Not yet recruiting
4
218
RoW
Evogliptin
Asan Medical Center, REDNVIA
CAVD
09/24
09/24
NCT05143177: A Study to Evaluate the Efficacy and Safety of DA-1229 (Evogliptin) in Patient's Calcific Aortic Valve Disease With Mild to Moderate Aortic Stenosis (EVOID-AS)

Recruiting
2/3
580
Canada, US
Evogliptin, DA-1229, Placebo
REDNVIA Co., Ltd.
Calcific Aortic Valve Disease
05/26
12/26
NCT04055883: Clinical Study to Evaluate Efficacy and Safety of DA-1229 in Patients With CAVD

Completed
2
228
RoW
DA-1229
Dong-A ST Co., Ltd.
Calcific Aortic Valve Disease
02/23
02/23
NCT05817097: Effect of Dipeptidyl-4 Inhibitors in Reducing Stroke Severity, From HIRA Database

Not yet recruiting
N/A
22119
NA
Dipeptidyl peptidase-4 inhibitor, A10BH07, EVOGLIPTIN, Suganon Tab
Ajou University School of Medicine, Dong-A ST Co., Ltd.
Cerebral Infarction, Infarction, Brain, Dipeptidyl-Peptidase IV Inhibitors
12/24
12/24
Growtropin-II (somatropin biosimilar) / Dong-A
NCT04798690: Long-term Safety and Effectiveness of Growtropin®-II Treatment in Children With Short Stature

Recruiting
N/A
2500
RoW
Dong-A ST Co., Ltd.
Growth Hormone Deficiency, Idiopathic Short Stature, Turner Syndrome, Small for Gestational Age
12/31
12/31
Dulastin (tripegfilgrastim) / Dong-A
SWOG S1826, NCT03907488: Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma

Active, not recruiting
3
994
Canada, US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Brentuximab Vedotin, ADC SGN-35, Adcetris, Anti-CD30 Antibody-Drug Conjugate SGN-35, Anti-CD30 Monoclonal Antibody-MMAE SGN-35, Anti-CD30 Monoclonal Antibody-Monomethylauristatin E SGN-35, cAC10-vcMMAE, SGN 35, SGN-35, SGN35, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Dacarbazine, 4-(Dimethyltriazeno)imidazole-5-carboxamide, 5-(Dimethyltriazeno)imidazole-4-carboxamide, Asercit, Biocarbazine, Dacarbazina, Dacarbazina Almirall, Dacarbazine - DTIC, Dacatic, Dakarbazin, Deticene, Detimedac, DIC, Dimethyl (triazeno) imidazolecarboxamide, Dimethyl Triazeno Imidazol Carboxamide, Dimethyl Triazeno Imidazole Carboxamide, dimethyl-triazeno-imidazole carboxamide, Dimethyl-triazeno-imidazole-carboximide, DTIC, DTIC-Dome, Fauldetic, Imidazole Carboxamide, Imidazole Carboxamide Dimethyltriazeno, WR-139007, Doxorubicin Hydrochloride, 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI), ADM, Adriacin, Adriamycin, Adriamycin Hydrochloride, Adriamycin PFS, Adriamycin RDF, ADRIAMYCIN, HYDROCHLORIDE, Adriamycine, Adriblastina, Adriblastine, Adrimedac, Chloridrato de Doxorrubicina, DOX, DOXO-CELL, Doxolem, Doxorubicin HCl, Doxorubicin.HCl, Doxorubin, Farmiblastina, FI 106, FI-106, FI106, hydroxydaunorubicin, Rubex, Filgrastim, Filgrastim Biosimilar Filgrastim-sndz, Filgrastim Biosimilar Tbo-filgrastim, Filgrastim XM02, Filgrastim-aafi, Filgrastim-ayow, Filgrastim-sndz, G-CSF, Granix, Neupogen, Neutroval, Nivestim, Nivestym, r-metHuG-CSF, Recombinant Methionyl Human Granulocyte Colony Stimulating Factor, Releuko, rG-CSF, Tbo-filgrastim, Tevagrastim, XM02, Zarxio, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Nivolumab, ABP 206, BCD-263, BMS 936558, BMS-936558, BMS936558, CMAB819, MDX 1106, MDX-1106, MDX1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO 4538, ONO-4538, ONO4538, Opdivo, Pegfilgrastim, Dulastin, Filgrastim SD-01, filgrastim-SD/01, Fulphila, Fylnetra, G-Lasta, HSP-130, Jinyouli, Neulasta, Neulastim, Neupopeg, Nyvepria, PEG-filgrastim, Pegcyte, Pegfilgrastim Biosimilar HSP-130, Pegfilgrastim Biosimilar Nyvepria, Pegfilgrastim Biosimilar Pegcyte, Pegfilgrastim Biosimilar PF-06881894, Pegfilgrastim Biosimilar Udenyca, Pegfilgrastim Biosimilar Ziextenzo, Pegfilgrastim-apgf, Pegfilgrastim-bmez, Pegfilgrastim-cbqv, Pegfilgrastim-fpgk, Pegfilgrastim-jmdb, Pegfilgrastim-pbbk, Pegylated G-CSF, Pegylated GCSF, Pegylated Granulocyte Colony Stimulating Factor, PF-06881894, SD-01, SD-01 sustained duration G-CSF, Stimufend, Tripegfilgrastim, Udenyca, Ziextenzo, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, PT, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Radiation Therapy, Cancer Radiotherapy, Energy Type, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation, Vinblastine Sulfate, 29060 LE, 29060-LE, Exal, Velban, Velbe, Velsar, VINCALEUKOBLASTINE
National Cancer Institute (NCI)
Ann Arbor Stage III Hodgkin Lymphoma, Ann Arbor Stage III Lymphocyte-Depleted Classic Hodgkin Lymphoma, Ann Arbor Stage III Mixed Cellularity Classic Hodgkin Lymphoma, Ann Arbor Stage III Nodular Sclerosis Classic Hodgkin Lymphoma, Ann Arbor Stage IV Hodgkin Lymphoma, Ann Arbor Stage IV Lymphocyte-Depleted Classic Hodgkin Lymphoma, Ann Arbor Stage IV Mixed Cellularity Classic Hodgkin Lymphoma, Ann Arbor Stage IV Nodular Sclerosis Classic Hodgkin Lymphoma, Classic Hodgkin Lymphoma, Lymphocyte-Rich Classic Hodgkin Lymphoma
03/24
03/26
NCT06520176: Comparison Study of EAP and CG Regimens for Mobilizing Hematopoietic Stem Cells in Multiple Myeloma Patients

Recruiting
3
99
RoW
Etoposide, VP-16, Cytarabine, Ara-C, Pegfilgrastim, PEG-rhG-CSF, Cyclophosphamide, Cy, G-CSF, Granulocyte Colony Stimulating Factor
The Affiliated People's Hospital of Ningbo University, First Affiliated Hospital of Zhejiang University, First Affiliated Hospital of Wenzhou Medical University, Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University, The Central Hospital of Lishui City, Jinhua People's Hospital, Shaoxing People's Hospital, Shaoxing Second Hospital, Zhejiang Provincial Tongde Hospital, Taizhou Hospital, Dongyang People's Hospital, Affiliated Hospital of Jiaxing University, Huizhou Municipal Central Hospital, Second Affiliated Hospital of Wenzhou Medical University, Ningbo Medical Center Lihuili Hospital, Jinhua Municipal Central Hospital
Multiple Myeloma, Hematopoietic Stem Cell Mobilization
12/26
12/26
NCT04759586: Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma

Active, not recruiting
3
244
Canada, US, RoW
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Asta B 518, B 518, B-518, B518, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR 138719, WR- 138719, WR-138719, WR138719, Doxorubicin Hydrochloride, 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI), ADM, Adriacin, Adriamycin, Adriamycin Hydrochloride, Adriamycin PFS, Adriamycin RDF, ADRIAMYCIN, HYDROCHLORIDE, Adriamycine, Adriblastina, Adriblastine, Adrimedac, Chloridrato de Doxorrubicina, DOX, DOXO-CELL, Doxolem, Doxorubicin HCl, Doxorubicin.HCl, Doxorubin, Farmiblastina, FI 106, FI-106, FI106, hydroxydaunorubicin, Rubex, Echocardiography Test, EC, Echocardiography, Etoposide Phosphate, Etopophos, Filgrastim, Filgrastim Biosimilar Filgrastim-sndz, Filgrastim Biosimilar Tbo-filgrastim, Filgrastim XM02, Filgrastim-aafi, Filgrastim-ayow, Filgrastim-sndz, G-CSF, Granix, Neupogen, Neutroval, Nivestim, Nivestym, r-metHuG-CSF, Recombinant Methionyl Human Granulocyte Colony Stimulating Factor, Releuko, rG-CSF, Tbo-filgrastim, Tevagrastim, XM02, Zarxio, Lumbar Puncture, LP, Spinal Tap, Nivolumab, ABP 206, BCD-263, BMS 936558, BMS-936558, BMS936558, CMAB819, MDX 1106, MDX-1106, MDX1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO 4538, ONO-4538, ONO4538, Opdivo, Pegfilgrastim, Dulastin, Filgrastim SD-01, filgrastim-SD/01, Fulphila, Fylnetra, G-Lasta, HSP-130, Jinyouli, Neulasta, Neulastim, Neupopeg, Nyvepria, PEG-filgrastim, Pegcyte, Pegfilgrastim Biosimilar HSP-130, Pegfilgrastim Biosimilar Nyvepria, Pegfilgrastim Biosimilar Pegcyte, Pegfilgrastim Biosimilar PF-06881894, Pegfilgrastim Biosimilar Udenyca, Pegfilgrastim Biosimilar Ziextenzo, Pegfilgrastim-apgf, Pegfilgrastim-bmez, Pegfilgrastim-cbqv, Pegfilgrastim-fpgk, Pegfilgrastim-jmdb, Pegfilgrastim-pbbk, Pegylated G-CSF, Pegylated GCSF, Pegylated Granulocyte Colony Stimulating Factor, PF-06881894, SD-01, SD-01 sustained duration G-CSF, Stimufend, Tripegfilgrastim, Udenyca, Ziextenzo, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, PT, Prednisolone, (11beta)-11,17,21-Trihydroxypregna-1,4-diene-3,20-dione, .delta.1-Hydrocortisone, Adnisolone, Aprednislon, Capsoid, Cortalone, Cortisolone, Dacortin H, Decaprednil, Decortin H, Delta(1)Hydrocortisone, Delta- Cortef, Delta-Cortef, Delta-Diona, Delta-F, Delta-Phoricol, Delta1-dehydro-hydrocortisone, Deltacortril, Deltahydrocortisone, Deltasolone, Deltidrosol, Dhasolone, Di-Adreson-F, Dontisolon D, Estilsona, Fisopred, Frisolona, Gupisone, Hostacortin H, Hydeltra, Hydeltrasol, Klismacort, Kuhlprednon, Lenisolone, Lepi-Cortinolo, Linola-H N, Linola-H-Fett N, Longiprednil, Metacortandralone, Meti Derm, Meticortelone, Opredsone, Panafcortelone, Precortisyl, Pred-Clysma, Predeltilone, Predni-Coelin, Predni-Helvacort, Prednicortelone, Prednisolonum, Prelone, Prenilone, Sterane, Prednisone, .delta.1-Cortisone, 1, 2-Dehydrocortisone, Adasone, Cortancyl, Dacortin, DeCortin, Decortisyl, Decorton, Delta 1-Cortisone, Delta-Dome, Deltacortene, Deltacortisone, Deltadehydrocortisone, Deltasone, Deltison, Deltra, Econosone, Lisacort, Meprosona-F, Metacortandracin, Meticorten, Ofisolona, Orasone, Panafcort, Panasol-S, Paracort, Perrigo Prednisone, PRED, Predicor, Predicorten, Prednicen-M, Prednicort, Prednidib, Prednilonga, Predniment, Prednisone Intensol, Prednisonum, Prednitone, Promifen, Rayos, Servisone, SK-Prednisone, Radiation Therapy, Cancer Radiotherapy, Energy Type, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation, Rituximab, ABP 798, ABP-798, ABP798, BI 695500, BI-695500, BI695500, Blitzima, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT P10, CT-P10, CTP10, GP 2013, GP-2013, GP2013, IDEC 102, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, IDEC102, Ikgdar, Mabtas, MabThera, Monoclonal Antibody IDEC-C2B8, PF 05280586, PF-05280586, PF05280586, Riabni, Ritemvia, Rituxan, Rituximab ABBS, Rituximab ARRX, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar GP2013, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, Rituximab Biosimilar SIBP-02, rituximab biosimilar TQB2303, Rituximab PVVR, Rituximab-abbs, Rituximab-arrx, Rituximab-blit, Rituximab-pvvr, Rituximab-rite, Rituximab-rixa, Rituximab-rixi, Rixathon, Riximyo, RTXM 83, RTXM-83, RTXM83, Ruxience, Truxima, Rituximab and Hyaluronidase Human, Rituxan Hycela, Rituximab Plus Hyaluronidase, Rituximab/Hyaluronidase, Rituximab/Hyaluronidase Human, Vincristine Sulfate, Kyocristine, Leurocristine Sulfate, Leurocristine, sulfate, Oncovin, Vincasar, Vincosid, Vincrex, Vincristine, sulfate
National Cancer Institute (NCI)
Primary Mediastinal Large B-Cell Lymphoma
12/27
12/27
NCT04628767: Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer

Recruiting
2/3
249
US
Biopsy Procedure, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Doxorubicin Hydrochloride, 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI), ADM, Adriacin, Adriamycin, Adriamycin Hydrochloride, Adriamycin PFS, Adriamycin RDF, ADRIAMYCIN, HYDROCHLORIDE, Adriamycine, Adriblastina, Adriblastine, Adrimedac, Chloridrato de Doxorrubicina, DOX, DOXO-CELL, Doxolem, Doxorubicin HCl, Doxorubicin.HCl, Doxorubin, Farmiblastina, FI 106, FI-106, FI106, hydroxydaunorubicin, Rubex, Durvalumab, Imfinzi, Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer, MEDI 4736, MEDI-4736, MEDI4736, Gemcitabine Hydrochloride, dFdCyd, Difluorodeoxycytidine Hydrochloride, Gemcitabine HCI, Gemzar, LY 188011, LY-188011, LY188011, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Methotrexate, Abitrexate, Alpha-Methopterin, Amethopterin, Brimexate, CL 14377, CL-14377, Emtexate, Emthexat, Emthexate, Farmitrexat, Fauldexato, Folex, Folex PFS, Jylamvo, Lantarel, Ledertrexate, Lumexon, Maxtrex, Medsatrexate, Metex, Methoblastin, Methotrexate LPF, Methotrexate Methylaminopterin, Methotrexatum, Metotrexato, Metrotex, Mexate, Mexate-AQ, MTX, Novatrex, Rheumatrex, Texate, Tremetex, Trexeron, Trixilem, WR-19039, Pegfilgrastim, Dulastin, Filgrastim SD-01, filgrastim-SD/01, Fulphila, Fylnetra, G-Lasta, HSP-130, Jinyouli, Neulasta, Neulastim, Neupopeg, Nyvepria, PEG-filgrastim, Pegcyte, Pegfilgrastim Biosimilar HSP-130, Pegfilgrastim Biosimilar Nyvepria, Pegfilgrastim Biosimilar Pegcyte, Pegfilgrastim Biosimilar PF-06881894, Pegfilgrastim Biosimilar Udenyca, Pegfilgrastim Biosimilar Ziextenzo, Pegfilgrastim-apgf, Pegfilgrastim-bmez, Pegfilgrastim-cbqv, Pegfilgrastim-fpgk, Pegfilgrastim-jmdb, Pegfilgrastim-pbbk, Pegylated G-CSF, Pegylated GCSF, Pegylated Granulocyte Colony Stimulating Factor, PF-06881894, SD-01, SD-01 sustained duration G-CSF, Stimufend, Tripegfilgrastim, Udenyca, Ziextenzo, Therapeutic Conventional Surgery, Vinblastine Sulfate, 29060 LE, 29060-LE, Exal, Velban, Velbe, Velsar, VINCALEUKOBLASTINE
National Cancer Institute (NCI)
Renal Pelvis and Ureter Urothelial Carcinoma
09/27
09/27
S0533, NCT00334815: Combination Chemotherapy, Radiation Therapy, and Bevacizumab in Treating Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery

Checkmark P1/2 data - ASCO/ASTRO/IASLC 2012
Sep 2012 - Sep 2012: P1/2 data - ASCO/ASTRO/IASLC 2012
Checkmark P1/2 data-ASCO
Jun 2012 - Jun 2012: P1/2 data-ASCO
Checkmark P2 data 1st line NSCLC
More
Active, not recruiting
2
29
US
Bevacizumab, ABP 215, ABP-215, ABP215, Alymsys, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF Monoclonal Antibody SIBP04, Anti-VEGF rhuMAb, Avastin, Avzivi, Aybintio, BAT 1706, BAT-1706, BAT1706, BAT1706 Biosimilar, Bevacizumab awwb, Bevacizumab Biosimilar ABP 215, Bevacizumab Biosimilar BAT1706, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Bevacizumab Biosimilar CBT 124, Bevacizumab Biosimilar CT-P16, Bevacizumab Biosimilar FKB238, Bevacizumab Biosimilar GB-222, Bevacizumab Biosimilar HD204, Bevacizumab Biosimilar HLX04, Bevacizumab Biosimilar IBI305, Bevacizumab Biosimilar LY01008, Bevacizumab Biosimilar MB02, Bevacizumab Biosimilar MIL60, Bevacizumab Biosimilar Mvasi, Bevacizumab Biosimilar MYL-1402O, Bevacizumab Biosimilar QL 1101, Bevacizumab Biosimilar QL1101, Bevacizumab Biosimilar RPH-001, Bevacizumab Biosimilar SCT501, Bevacizumab Biosimilar Zirabev, Bevacizumab-adcd, Bevacizumab-awwb, Bevacizumab-aybi, Bevacizumab-bvzr, Bevacizumab-equi, Bevacizumab-maly, Bevacizumab-onbe, Bevacizumab-tnjn, BP102, BP102 Biosimilar, CT P16, CT-P16, CTP16, Equidacent, FKB 238, FKB-238, FKB238, HD204, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, MB 02, MB-02, MB02, Mvasi, MYL-1402O, Onbevzi, Oyavas, PF 06439535, PF-06439535, PF06439535, QL1101, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, SCT501, SIBP 04, SIBP-04, SIBP04, Vegzelma, Zirabev, Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Docetaxel, Docecad, RP 56976, RP-56976, RP56976, Taxotere, Taxotere Injection Concentrate, Etoposide, Demethyl Epipodophyllotoxin Ethylidine Glucoside, EPEG, Lastet, Toposar, Vepesid, VP 16, VP 16-213, VP 16213, VP-16, VP-16-213, VP-16213, VP16, VP16213, Filgrastim, Filgrastim Biosimilar Filgrastim-sndz, Filgrastim Biosimilar Tbo-filgrastim, Filgrastim XM02, Filgrastim-aafi, Filgrastim-ayow, Filgrastim-sndz, G-CSF, Granix, Neupogen, Neutroval, Nivestim, Nivestym, r-metHuG-CSF, Recombinant Methionyl Human Granulocyte Colony Stimulating Factor, Releuko, rG-CSF, Tbo-filgrastim, Tevagrastim, XM02, Zarxio, Pegfilgrastim, Dulastin, Filgrastim SD-01, filgrastim-SD/01, Fulphila, Fylnetra, G-Lasta, HSP-130, Jinyouli, Neulasta, Neulastim, Neupopeg, Nyvepria, PEG-filgrastim, Pegcyte, Pegfilgrastim Biosimilar HSP-130, Pegfilgrastim Biosimilar Nyvepria, Pegfilgrastim Biosimilar Pegcyte, Pegfilgrastim Biosimilar PF-06881894, Pegfilgrastim Biosimilar Udenyca, Pegfilgrastim Biosimilar Ziextenzo, Pegfilgrastim-apgf, Pegfilgrastim-bmez, Pegfilgrastim-cbqv, Pegfilgrastim-fpgk, Pegfilgrastim-jmdb, Pegfilgrastim-pbbk, Pegylated G-CSF, Pegylated GCSF, Pegylated Granulocyte Colony Stimulating Factor, PF-06881894, SD-01, SD-01 sustained duration G-CSF, Stimufend, Tripegfilgrastim, Udenyca, Ziextenzo, Radiation Therapy, Cancer Radiotherapy, Energy Type, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation
National Cancer Institute (NCI)
Lung Adenocarcinoma, Lung Adenosquamous Carcinoma, Lung Large Cell Carcinoma, Lung Squamous Cell Carcinoma, Minimally Invasive Lung Adenocarcinoma, Stage IIIA Lung Non-Small Cell Cancer AJCC v7, Stage IIIB Lung Non-Small Cell Cancer AJCC v7
07/14
02/26
Dulastin, NCT06135896: Tripegfilgrastim Trial to Reduce the Risk of Severe Neutropenia in Patients With Unresectable Pancreaticobiliary Cancers

Recruiting
2
98
RoW
Tripegfilgrastim, Dulastin
National Cancer Center, Korea, Seoul National University Hospital
Unresectable Pancreatic Cancer, Unresectable Bile Duct Carcinoma, Unresectable Biliary Tract Carcinoma
06/26
06/26
NCT06738368: Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia

Not yet recruiting
2
30
US
Asparaginase Erwinia chrysanthemi, Asparaginase Erwinia chrysanthemi (Recombinant)-rywn, Asparaginase Erwinia chrysanthemi, Recombinant-rywn, Asparaginase Erwinia chrysanthemi-rywn, Crisantaspase, Crisantaspase Biobetter JZP-458, Crisantaspasum, Enrylaze, Erwinase, Erwinaze, JZP 458, JZP-458, JZP458, PF743, RC-P JZP-458, Recombinant Asparaginase erwinia chrysanthemi JZP-458, Recombinant Crisantaspase JZP-458, Recombinant Erwinia asparaginase JZP-458, Rylaze, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Collection, Collection, Bone Marrow, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Asta B 518, B 518, B-518, B518, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR 138719, WR- 138719, WR-138719, WR138719, Doxorubicin, Adriablastin, Hydroxydaunomycin, Hydroxyl Daunorubicin, Hydroxyldaunorubicin, Etoposide, Demethyl Epipodophyllotoxin Ethylidine Glucoside, EPEG, Lastet, Toposar, Vepesid, VP 16, VP 16-213, VP 16213, VP-16, VP-16-213, VP-16213, VP16, VP16213, Filgrastim, Filgrastim Biosimilar Filgrastim-sndz, Filgrastim Biosimilar Tbo-filgrastim, Filgrastim XM02, Filgrastim-aafi, Filgrastim-ayow, Filgrastim-sndz, G-CSF, Granix, Neupogen, Neutroval, Nivestim, Nivestym, r-metHuG-CSF, Recombinant Methionyl Human Granulocyte Colony Stimulating Factor, Releuko, rG-CSF, Tbo-filgrastim, Tevagrastim, XM02, Zarxio, Pegfilgrastim, Dulastin, Filgrastim SD-01, filgrastim-SD/01, Fulphila, Fylnetra, G-Lasta, HSP-130, Jinyouli, Neulasta, Neulastim, Neupopeg, Nyvepria, PEG-filgrastim, Pegcyte, Pegfilgrastim Biosimilar HSP-130, Pegfilgrastim Biosimilar Nyvepria, Pegfilgrastim Biosimilar Pegcyte, Pegfilgrastim Biosimilar PF-06881894, Pegfilgrastim Biosimilar Udenyca, Pegfilgrastim Biosimilar Ziextenzo, Pegfilgrastim-apgf, Pegfilgrastim-bmez, Pegfilgrastim-cbqv, Pegfilgrastim-fpgk, Pegfilgrastim-jmdb, Pegfilgrastim-pbbk, Pegylated G-CSF, Pegylated GCSF, Pegylated Granulocyte Colony Stimulating Factor, PF-06881894, SD-01, SD-01 sustained duration G-CSF, Stimufend, Tripegfilgrastim, Udenyca, Ziextenzo, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Prednisone, .delta.1-Cortisone, 1, 2-Dehydrocortisone, Adasone, Cortancyl, Dacortin, DeCortin, Decortisyl, Decorton, Delta 1-Cortisone, Delta-Dome, Deltacortene, Deltacortisone, Deltadehydrocortisone, Deltasone, Deltison, Deltra, Econosone, Lisacort, Meprosona-F, Metacortandracin, Meticorten, Ofisolona, Orasone, Panafcort, Panasol-S, Paracort, Perrigo Prednisone, PRED, Predicor, Predicorten, Prednicen-M, Prednicort, Prednidib, Prednilonga, Predniment, Prednisone Intensol, Prednisonum, Prednitone, Promifen, Rayos, Servisone, SK-Prednisone, Rituximab, ABP 798, BI 695500, BI-695500, BI695500, Blitzima, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC 102, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, IDEC102, Ikgdar, Mabtas, MabThera, Monoclonal Antibody IDEC-C2B8, PF 05280586, PF-05280586, PF05280586, Riabni, Ritemvia, Rituxan, Rituximab ABBS, Rituximab ARRX, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, Rituximab Biosimilar SIBP-02, rituximab biosimilar TQB2303, Rituximab PVVR, Rituximab-abbs, Rituximab-arrx, Rituximab-blit, Rituximab-pvvr, Rituximab-rite, Rituximab-rixa, Rituximab-rixi, Rixathon, Riximyo, RTXM 83, RTXM-83, RTXM83, Ruxience, Truxima, Vincristine, LCR, Leurocristine, VCR, Vincrystine
University of Washington, Jazz Pharmaceuticals
B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, T Acute Lymphoblastic Leukemia
12/27
06/28
NCT04684368: A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT

Recruiting
2
160
Canada, US, RoW
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, JM8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Etoposide, Demethyl Epipodophyllotoxin Ethylidine Glucoside, EPEG, Lastet, Toposar, Vepesid, VP 16, VP 16-213, VP 16213, VP-16, VP-16-213, VP16, Filgrastim, Filgrastim Biosimilar Filgrastim-sndz, Filgrastim Biosimilar Tbo-filgrastim, Filgrastim XM02, Filgrastim-aafi, Filgrastim-ayow, Filgrastim-sndz, G-CSF, Granix, Neupogen, Neutroval, Nivestym, r-metHuG-CSF, Recombinant Methionyl Human Granulocyte Colony Stimulating Factor, Releuko, rG-CSF, Tbo-filgrastim, Tevagrastim, XM02, Zarxio, Ifosfamide, Asta Z 4942, Asta Z-4942, Cyfos, Holoxan, Holoxane, Ifex, IFO, IFO-Cell, Ifolem, Ifomida, Ifomide, Ifosfamidum, Ifoxan, IFX, Iphosphamid, Iphosphamide, Iso-Endoxan, Isoendoxan, Isophosphamide, Mitoxana, MJF 9325, MJF-9325, Naxamide, Seromida, Tronoxal, Z 4942, Z-4942, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Mesna, 2-Mercaptoethanesulfonate, Sodium Salt, Ausobronc, D-7093, Filesna, Mercaptoethane Sulfonate, Mercaptoethanesulfonate, Mesnex, Mesnil, Mesnum, Mexan, Mistabron, Mistabronco, Mitexan, Mucofluid, Mucolene, UCB 3983, Uromitexan, Ziken, Pegfilgrastim, Dulastin, Filgrastim SD-01, filgrastim-SD/01, Fulphila, HSP-130, Jinyouli, Neulasta, Neulastim, Neupopeg, Nyvepria, PEG-filgrastim, Pegcyte, Pegfilgrastim Biosimilar HSP-130, Pegfilgrastim Biosimilar Nyvepria, Pegfilgrastim Biosimilar Pegcyte, Pegfilgrastim Biosimilar PF-06881894, Pegfilgrastim Biosimilar Udenyca, Pegfilgrastim Biosimilar Ziextenzo, Pegfilgrastim-apgf, Pegfilgrastim-bmez, Pegfilgrastim-cbqv, Pegfilgrastim-jmdb, Pegylated G-CSF, Pegylated GCSF, Pegylated Granulocyte Colony Stimulating Factor, PF-06881894, SD-01, SD-01 sustained duration G-CSF, Tripegfilgrastim, Udenyca, Ziextenzo, Peripheral Blood Stem Cell Transplantation, PBPC transplantation, PBSCT, Peripheral Blood, Peripheral Blood Progenitor Cell Transplantation, PERIPHERAL BLOOD STEM CELL TRANSPLANT, Peripheral Stem Cell Support, Peripheral Stem Cell Transplant, Peripheral Stem Cell Transplantation, Questionnaire Administration, Radiation Therapy, Cancer Radiotherapy, Energy Type, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation, Second-Look Surgery, Reoperation, Repeat Surgery, Second Look, Surgical Revision, Thiotepa, 1,1',1''-Phosphinothioylidynetrisaziridine, Girostan, N,N', N''-Triethylenethiophosphoramide, Oncotiotepa, STEPA, Tepadina, TESPA, Tespamin, Tespamine, Thio-Tepa, Thiofosfamide, Thiofozil, Thiophosphamide, Thiophosphoamide, Thiophosphoramide, Thiotef, Tifosyl, TIO TEF, Tio-tef, Triethylene Thiophosphoramide, Triethylenethiophosphoramide, Tris(1-aziridinyl)phosphine sulfide, TSPA, WR 45312
Children's Oncology Group, National Cancer Institute (NCI)
Central Nervous System Nongerminomatous Germ Cell Tumor, Choriocarcinoma, Embryonal Carcinoma, Immature Teratoma, Malignant Teratoma, Mixed Germ Cell Tumor, Pineal Region Germ Cell Tumor, Pineal Region Immature Teratoma, Pineal Region Yolk Sac Tumor, Suprasellar Germ Cell Tumor
12/29
12/29
NCT03220022: Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell Lymphomas

Active, not recruiting
1
54
US
Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Asta B 518, B 518, B-518, B518, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR 138719, WR- 138719, WR-138719, WR138719, Doxorubicin Hydrochloride, 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI), ADM, Adriacin, Adriamycin, Adriamycin Hydrochloride, Adriamycin PFS, Adriamycin RDF, ADRIAMYCIN, HYDROCHLORIDE, Adriamycine, Adriblastina, Adriblastine, Adrimedac, Chloridrato de Doxorrubicina, DOX, DOXO-CELL, Doxolem, Doxorubicin HCl, Doxorubicin.HCl, Doxorubin, Farmiblastina, FI 106, FI-106, FI106, hydroxydaunorubicin, Rubex, Etoposide, Demethyl Epipodophyllotoxin Ethylidine Glucoside, EPEG, Lastet, Toposar, Vepesid, VP 16, VP 16-213, VP 16213, VP-16, VP-16-213, VP-16213, VP16, VP16213, Filgrastim, Filgrastim Biosimilar Filgrastim-sndz, Filgrastim Biosimilar Tbo-filgrastim, Filgrastim XM02, Filgrastim-aafi, Filgrastim-ayow, Filgrastim-sndz, G-CSF, Granix, Neupogen, Neutroval, Nivestim, Nivestym, r-metHuG-CSF, Recombinant Methionyl Human Granulocyte Colony Stimulating Factor, Releuko, rG-CSF, Tbo-filgrastim, Tevagrastim, XM02, Zarxio, Ibrutinib, BTK Inhibitor PCI-32765, CRA 032765, CRA-032765, CRA032765, Imbruvica, PCI 32765, PCI-32765, PCI32765, Laboratory Biomarker Analysis, Pegfilgrastim, Dulastin, Filgrastim SD-01, filgrastim-SD/01, Fulphila, Fylnetra, G-Lasta, HSP-130, Jinyouli, Neulasta, Neulastim, Neupopeg, Nyvepria, PEG-filgrastim, Pegcyte, Pegfilgrastim Biosimilar HSP-130, Pegfilgrastim Biosimilar Nyvepria, Pegfilgrastim Biosimilar Pegcyte, Pegfilgrastim Biosimilar PF-06881894, Pegfilgrastim Biosimilar Udenyca, Pegfilgrastim Biosimilar Ziextenzo, Pegfilgrastim-apgf, Pegfilgrastim-bmez, Pegfilgrastim-cbqv, Pegfilgrastim-fpgk, Pegfilgrastim-jmdb, Pegfilgrastim-pbbk, Pegylated G-CSF, Pegylated GCSF, Pegylated Granulocyte Colony Stimulating Factor, PF-06881894, SD-01, SD-01 sustained duration G-CSF, Stimufend, Tripegfilgrastim, Udenyca, Ziextenzo, Pharmacological Study, Prednisone, .delta.1-Cortisone, 1, 2-Dehydrocortisone, Adasone, Cortancyl, Dacortin, DeCortin, Decortisyl, Decorton, Delta 1-Cortisone, Delta-Dome, Deltacortene, Deltacortisone, Deltadehydrocortisone, Deltasone, Deltison, Deltra, Econosone, Lisacort, Meprosona-F, Metacortandracin, Meticorten, Ofisolona, Orasone, Panafcort, Panasol-S, Paracort, Perrigo Prednisone, PRED, Predicor, Predicorten, Prednicen-M, Prednicort, Prednidib, Prednilonga, Predniment, Prednisone Intensol, Prednisonum, Prednitone, Promifen, Rayos, Servisone, SK-Prednisone, Rituximab, ABP 798, ABP-798, ABP798, BI 695500, BI-695500, BI695500, Blitzima, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT P10, CT-P10, CTP10, GP 2013, GP-2013, GP2013, IDEC 102, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, IDEC102, Ikgdar, Mabtas, MabThera, Monoclonal Antibody IDEC-C2B8, PF 05280586, PF-05280586, PF05280586, Riabni, Ritemvia, Rituxan, Rituximab ABBS, Rituximab ARRX, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar GP2013, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, Rituximab Biosimilar SIBP-02, rituximab biosimilar TQB2303, Rituximab PVVR, Rituximab-abbs, Rituximab-arrx, Rituximab-blit, Rituximab-pvvr, Rituximab-rite, Rituximab-rixa, Rituximab-rixi, Rixathon, Riximyo, RTXM 83, RTXM-83, RTXM83, Ruxience, Truxima, Vincristine Sulfate, Kyocristine, Leurocristine Sulfate, Leurocristine, sulfate, Oncovin, Vincasar, Vincosid, Vincrex, Vincristine, sulfate
National Cancer Institute (NCI)
AIDS-Related Lymphoma, Ann Arbor Stage II Diffuse Large B-Cell Lymphoma, Ann Arbor Stage III Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma
07/25
07/25
recoflavone (DA-6034) / GL PharmTech, AJU Pharm
NCT06291194: Efficacy and Safety of AJU-S56 5% in Dry Eye Syndrome Patients

Recruiting
3
396
RoW
AJU-S56 5%, Test Group, Placebo Group(Vehicle), Control Group
AJU Pharm Co., Ltd., GL Pharm Tech Corporation
Dry Eye Syndromes
05/24
05/24
NCT06337981: Efficacy and Safety of AJU-S56 in Dry Eye Syndrome Patients

Completed
2
99
RoW
(AJU-S56 5% and placebo), Test 1 group(AJU-S56 5% and placebo, each 1 drop/1time, 3times in a day), AJU-S56 5%, Test 2 group(AJU-S56 5%, 1 drop/1time, 6times in a day), Placebo(Vehicle), Placebo group(Vehicle, 1 drop/1time, 6times in a day)
AJU Pharm Co., Ltd., GL Pharm Tech Corporation
Dry Eye Syndromes
06/22
11/22
GLH8NDE-201, NCT04679883: Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of GLH8NDE in Patients With Dry Eye Disease

Not yet recruiting
2
99
RoW
5% GLH8NDE, Placebo
GL Pharm Tech Corporation
Dry Eye Syndromes
01/22
04/22
cenicriviroc (TBR-652) / Takeda, AbbVie
2015-002955-85: A phase II feasibility study to assess changes in patients who have been identified as having cognitive function impairment following the addition of a new drug to an existing effective regime of three HIV antiretrovirals drugs

Ongoing
2
10
Europe
Cenicriviroc, TBR-652, Tablet
Imperial College London, Imperial College Healthcare NHS Trust Biomedical Research Centre
Human Immunodeficiency Virus, HIV, Diseases [C] - Virus Diseases [C02]
 
 
I-SPY_COVID, NCT04488081: I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients

Recruiting
2
1500
US
Remdesivir, GS-5734, Imatinib Mesylate, Dexamethasone, Cenicriviroc, Icatibant, Firazyr, Apremilast, Otezla, dornase alfa, Pulmozyme, Celecoxib, celebrex, Famotidine, Pepcid, IC14, Aviptadil, Zyesami, narsoplimab, OMS721, Cyproheptadine, periactin, Cyclosporine, CsA
QuantumLeap Healthcare Collaborative, University of California, San Francisco, University of Pennsylvania, Emory University, University of Alabama at Birmingham, University of Colorado, Denver, University of Southern California, Yale University, Wake Forest University Health Sciences, Sanford Health, Long Beach Memorial Medical Center, Georgetown University, University of California, Davis, Hoag Memorial Hospital Presbyterian, Main Line Health, DHR Health Institute for Research and Development, University of California, Irvine, Corewell Health, Kaiser Permanente, University of Michigan, West Virginia University, University of Miami, University Hospitals Cleveland Medical Center, Virtua Health, M.D. Anderson Cancer Center
COVID-19
07/28
07/30
NCT05630885: A Study to Evaluate the Effects of Cenicriviroc Mesylate on Arterial Inflammation in People Living With HIV

Completed
2
110
US
CVC 150 mg, CVC 300 mg, Placebo for CVC 150 mg, Placebo for CVC 300 mg
National Institute of Allergy and Infectious Diseases (NIAID), AbbVie
HIV-1-infection
06/24
06/24
basroparib (STP1002) / Dong-A
NCT04505839: First-In-Human Dose-Escalation Study of STP1002 in Patients With Advanced-Stage Solid Tumors

Completed
1
32
US
STP1002, Basroparib
ST Pharm Co., Ltd., KCRN Research, LLC
Advanced Solid Tumor
03/23
03/23
Branigen (acetyl-L-carnitine) / Mitsubishi Tanabe, Dong-A, Leadiant Biosci
2011-006235-33: Comparison of two products (dextrorotatory enantiomer of thioctic acid - food supplement - and acetyl-l-carnitine - drug) in the treatment of sciatic nerve disease Confronto dell'azione di due prodotti (enantiomero destrogiro dell'acido tioctico - integratore alimentare - e acetil-l-carnitina - specialita' medicinale) nel trattamento delle sofferenze del nervo sciatico

Ongoing
4
100
Europe
THIOCTIC ACID, NA, Gastro-resistant tablet, Tablet, NICETILE*30CPR 500MG
MDM S.P.A., MDM S.p.A.
sensitive motor sciatic neuropathy neuropatie sensitivo motorie del nervo sciatico, sciatic nerve disease sofferenza del nervo sciatico, Diseases [C] - Nervous System Diseases [C10]
 
 
Sugamet SR (evogliptin/metformin) / Dong-A
NCT05739877: Phamacokinetics and Safety Profiles of DA-1229_01 2.5/500mg in Healthy Subjects at Fed State

Not yet recruiting
1
34
RoW
DA-1229_01 2.5/500mg (Before), DA-1229_01 2.5/500mg (After)
Dong-A ST Co., Ltd.
Healthy
04/23
04/23
NCT05739851: Phamacokinetics and Safety Profiles of DA-1229_01 2.5/500mg in Healthy Subjects at Fasting State

Not yet recruiting
1
40
RoW
DA-1229_01 2.5/500mg (Before), DA-1229_01 2.5/500mg (After)
Dong-A ST Co., Ltd.
Healthy
04/23
04/23
NCT05739903: Phamacokinetics and Safety Profiles of DA-1229_01 5/1000mg in Healthy Subjects at Fasting State

Not yet recruiting
1
40
RoW
DA-1229_01 5/1000mg (Before), DA-1229_01 5/1000mg (After)
Dong-A ST Co., Ltd.
Healthy
04/23
04/23
NCT05739916: Phamacokinetics and Safety Profiles of DA-1229_01 5/1000mg in Healthy Subjects at Fed State

Not yet recruiting
1
34
RoW
DA-1229_01 5/1000mg (Before), DA-1229_01 5/1000mg (After)
Dong-A ST Co., Ltd.
Healthy
04/23
04/23
DA-1241 / Dong-A
DA1241_NASH_IIa, NCT06054815: Study to Evaluate the Efficacy and Safety of DA-1241 in Subjects With Presumed NASH

Completed
2
109
US
DA-1241, Sitagliptin, DA-1241 Placebo, Sitagliptin Placebo
NeuroBo Pharmaceuticals Inc.
NON-ALCOHOLIC STEATOHEPATITIS
10/24
10/24
donepezil transdermal patch (DA-5207) / Dong-A
NCT04479865: Phase 1 Clinical Trial to Evaluate the Safety, PK and PD of DA-5207 TDS in Healthy Adults

Active, not recruiting
1
49
RoW
Aricept 5mg Tablet, Aricept 10mg Tablet, DA-5207 150mg, DA-5207 170mg
Dong-A ST Co., Ltd.
Healthy
12/20
04/21
NCT05127746: Phase 1 Clinical Trial of DA-5207 in Healthy Adults

Completed
1
51
RoW
Aricept 5mg Tablet, Aricept 10mg Tablet, DA-5207 A, DA-5207 B
Dong-A ST Co., Ltd.
Healthy
12/22
12/22
retlirafusp alfa (SHR-1701) / Jiangsu Hengrui Pharma
SHR-1701-III-309, NCT05179239: A Study of SHR-1701 Plus Platinum-containing Chemotherapy With or Without BP102 (Bevacizumab) as First-line Treatment in Cervical Cancer

Terminated
3
31
RoW
SHR-1701 + paclitaxel + cisplatin/carboplatin + BP102, SHR-1701 + paclitaxel + cisplatin/carboplatin± BP102, Placebo + paclitaxel + cisplatin/carboplatin ± BP102
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Cervical Cancer
08/24
08/24
SHR-1701-III-310, NCT05132413: A Study of SHR-1701 Plus Bevacizumab and Chemotherapy in Non-Small-Cell-Lung-Cancer

Not yet recruiting
3
561
NA
SHR-1701 + Pemetrexed Disodium + cisplatin/carboplatin + bevacizumab, Placebo + SHR-1701 + Pemetrexed Disodium+ cisplatin/carboplatin, Placebo 1 + Placebo 2 +Pemetrexed Disodium + cisplatin/carboplatin
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Advanced or Metastatic Non-squamous Non-small-cell Lung Cancer
12/24
12/24
SHR-1701-III-307, NCT04950322: A Trial of SHR1701 Plus Chemotherapy in Patients With Gastric or Gastroesophageal Cancer

Active, not recruiting
3
737
RoW
SHR-1701、CAPOX, Placebo、CAPOX
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Gastric or Gastroesophageal Junction Cancer
05/24
10/25
SHR-1701-III-301, NCT04856787: A Clinical Studyf of SHR-1701 or Placebo in Combination With BP102 and XELOX in the First-line Treatment of mCRC

Terminated
2/3
62
RoW
SHR-1701、 BP102 、XELOX, placebo、 BP102、 XELOX
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Metastatic Colorectal Cancer (mCRC)
04/24
04/24
SHR-1701-III-308, NCT05149807: Clinical Study of SHR-1701 Plus Chemotherapy as Perioperative Treatment in Subjects With Gastric Cancer

Terminated
2/3
81
RoW
SHR-1701 injection, Placebo
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Perioperative Treatment in Subjects With Locally Advanced Resectable Gastric Cancer or Gastroesophageal Junction Cancer
04/24
04/24
SHR-1701-Ⅱ-206, NCT04699968: A Trial of SHR-1701 With or Without Famitinib in Patients With Advanced or Metastatic NSCLC

Withdrawn
2
168
NA
SHR-1701，Famitinib, SHR-1701
Jiangsu HengRui Medicine Co., Ltd.
Non-Small-Cell Lung Cancer
11/21
11/21
SHR-1701-II-207-LC, NCT04974957: Study of SHR-1701 Plus BP102 in Subjects With Selected Solid Tumors

Not yet recruiting
2
71
NA
SHR-1701；BP102
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer
02/22
08/22
NCT04560244: A Trial of SHR1701 Combined With Radiotherapy for Metastatic Non-small Cell Lung Cancer Failure After First-line Treatment

Not yet recruiting
2
15
NA
SHR1701
Shandong Cancer Hospital and Institute
Non-Small-Cell Lung Cancer
09/22
12/22
SHR-1701-II-209, NCT04884009: A Trial of SHR-1701 in Combination With and Without Famitinib Malate in Patients With Extensive Stage Small Cell Lung Cancer

Not yet recruiting
2
106
NA
SHR-1701； Famitinib, SHR-1701
Jiangsu HengRui Medicine Co., Ltd.
Lung Cancer
12/22
12/22
SHR-1701-II-208, NCT04650633: SHR-1701 in Patients With Recurrent/Metastatic Scchn

Recruiting
2
130
RoW
SHR-1701
Jiangsu HengRui Medicine Co., Ltd.
Squamous Cell Carcinoma of Head and Neck
01/23
01/23
MULAN, NCT04355858: Molecularly Targeted Umbrella Study in Luminal Advanced Breast Cancer

Recruiting
2
319
RoW
SHR7390, Famitinib, SHR3162, Pyrotinib, Capecitabine, SHR1210, Everolimus, Nab paclitaxel, SHR2554, SHR3680, SHR6390, SHR1701, SERD, AI, VEGFi
Fudan University
Breast Cancer, Metastatic Cancer
05/23
04/25
TRAILBLAZER, NCT04580498: A Trial of SHR-1701 With or Without Chemotherapy in Patients With Stage III NSCLC

Active, not recruiting
2
107
RoW
SHR-1701+Paclitaxel+carboplatin, SHR-1701
Jiangsu HengRui Medicine Co., Ltd.
Non-Small-Cell Lung Cancer
07/23
03/25
NCT05106023: To Explore the Efficacy and Safety of SHR-1701 Combined With Temozolomide in the Treatment of Advanced Melanoma

Recruiting
2
31
RoW
SHR-1701, SHR1701, Temozolomide
Yong Chen
Melanoma
09/23
12/23
FLYFLY, NCT04937972: SHR-1701 Combined With Fluzoparib in Lung Squamous Cell Carcinoma

Recruiting
2
71
RoW
SHR-1701 Combined With Fluazopalil
Hunan Province Tumor Hospital
Non-Small Cell Lung Cancer
12/24
06/25
NCT05177497: SHR-1701 for Consolidation Therapy After Concurrent Chemoradiotherapy in Inoperable Stage III NSCLC

Not yet recruiting
2
19
NA
SHR-1701
Shanghai Chest Hospital
NSCLC, Stage III
07/24
10/24
SHR-1701-II-213, NCT05300269: SHR-1701 in Combination With Chemotherapy and Radiotherapy in Locally Advanced Rectal Cancer

Recruiting
2
73
RoW
SHR-1701；Capecitabine；Oxaliplatin
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Locally Advanced Rectal Cancer
07/24
10/26
NCT06679673: SHR-1701 Combined with SHR2554 and BP102 for MCRC

Not yet recruiting
2
20
RoW
SHR-1701, BP102, SHR2554
Fudan University
Colorectal Cancer Metastatic
12/25
12/26
MA-GC-II-023, NCT06881017: Establishment of Precision Targeted Therapy Strategies for Advanced Gastric Cancer Based on Novel Molecular Subtyping

Not yet recruiting
2
140
NA
Trastuzumab, Adebrelimab, Apatinib, S-1, Capecitabine, Oxaliplatin, zolbetuximab, SHR-A1811, SHR-A1904, SHR-1701
China Medical University, China
Gastric Cancer, HER2 + Gastric Cancer, CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction, PD-L1 Positive
08/29
11/29
ChiCTR2300070675: SHR-1701 in combination with albumin paclitaxel and carboplatin for advanced head and neck squamous cell carcinoma

Not yet recruiting
2
43
 
SHR-1701, albumin paclitaxel, and carboplatin
Fudan University Shanghai Cancer Center; Fudan University Shanghai Cancer Center, Expenditure of department
Head and neck squamous cell carcinoma
 
 
SHR-A1811-Ib/II-205, NCT05671822: Ph1b/2 Study of the Safety and Efficacy of SHR-A1811 Combinations in Advanced HER2 Expression Gastric Cancer

Active, not recruiting
2
76
RoW
SHR-A1811 and SHR-1701, SHR-A1811 and capecitabine, SHR-A181, SHR-1701, and capecitabine, SHR-A1811, SHR-1316, and capecitabine, SHR-A1811, SHR-1316, capecitabine,and oxaliplatin, SHR-A1811, SHR-1316, and 5-FU, SHR-1316 and SHR-A1811, SHR-A1811and 5-FU
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
HER2 Expression Gastric Cancer/Gastroesophageal Junction Adenocarcinoma
04/25
07/26
SHR-1701-II-204, NCT04624217: A Trial of SHR-1701 in Combination With Gemcitabine and Albumin Paclitaxel in Patients With Pancreatic Cancer

Completed
1/2
56
RoW
SHR-1701, Gemcitabine and Albumin Paclitaxel
Jiangsu HengRui Medicine Co., Ltd.
Pancreatic Cancer
09/21
02/23
SHR-1701-II-207, NCT04856774: Trial of SHR-1701 Plus BP102 in Subjects With Selected Solid Tumors

Completed
1/2
81
RoW
SHR-1701；BP102
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Advanced Solid Tumors
03/24
03/24
SHR-1701-II-203-NPC, NCT05020925: SHR-1701 in Combination With Famitinib in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma

Not yet recruiting
1/2
30
RoW
SHR-1701, SHR-1701 Injection, Famitinib, SHR-1020
Jiangsu HengRui Medicine Co., Ltd.
Nasopharyngeal Carcinoma
05/22
02/24
SHR-1701-II-203, NCT04679038: A Trial of SHR-1701 in Combination With Famitinib in Patients With Advanced Solid Tumors

Recruiting
1/2
222
RoW
SHR-1701, Famitinib
Jiangsu HengRui Medicine Co., Ltd.
Solid Tumor
12/22
10/23
NCT04407741: Phase Ⅰ/Ⅱ Study of SHR2554 in Combination With SHR1701 in Patients With Advanced Solid Tumors and B-cell Lymphomas

Recruiting
1/2
100
RoW
SHR2554+SHR1701, SHR1701
Chinese PLA General Hospital
Solid Tumor, Lymphoma
12/24
12/25
NCT05896046: SHR1701 Alone or in Combination With SHR2554 in Relapsed or Refractory Classical Hodgkin Lymphoma

Recruiting
1/2
100
RoW
SHR2554+ SHR1701, SHR-1701
Chinese PLA General Hospital
Relapsed or Refractory Hodgkin Lymphoma
06/25
06/26
SHR-1701-215, NCT05503888: Phase Ib/II Study of Almonertinib Combined With SHR-1701 in the Treatment of Relapsed or Advanced Non-small Cell Lung Cancer

Not yet recruiting
1/2
160
NA
Almonertinib combined with SHR-1701, Almonertinib
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Relapsed or Advanced Non-small Cell Lung Cancer
07/27
07/27
SHR-1701-I-103, NCT04282070: SHR-1701 in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma

Active, not recruiting
1
91
RoW
SHR-1701, SHR-1701 Injection, Gemcitabine, Gemcitabine Hydrochloride for Injection, Cisplatin, Cisplatin Injection, Albumin Paclitaxel, nab-Paclitaxel
Jiangsu HengRui Medicine Co., Ltd.
Nasopharyngeal Carcinoma
04/22
12/22
SHR-1701-I-101, NCT03710265: SHR-1701 in Metastatic or Locally Advanced Solid Tumors

Recruiting
1
206
RoW
SHR-1701
Jiangsu HengRui Medicine Co., Ltd.
Solid Tumor
12/22
12/22
NCT05198817: A Trial of SHR-2002 Injection or Combined With Other Anti-cancer Medication in Advanced Malignant Tumors of Patients

Enrolling by invitation
1
240
RoW
SHR-2002 injection、Camrelizumab for Injection, SHR-1316 injection, SHR-1701 injection
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Advanced Malignant Tumors
01/23
06/23
SHR-1701-001AUS, NCT04324814: A Trial of SHR-1701 in Subjects With Advanced Solid Tumors

Completed
1
41
RoW
SHR-1701
Atridia Pty Ltd.
Advanced Solid Tumor
02/23
02/23
SHR-1701-I-102, NCT03774979: SHR-1701 in Subjects With Metastatic or Locally Advanced Solid Tumors

Active, not recruiting
1
193
RoW
SHR-1701
Jiangsu HengRui Medicine Co., Ltd.
Solid Tumor
03/23
12/23
NCT05048134: A Phase I Study of HRS2300 or Combined With SHR-1316 or SHR-1701 or Trametinib or Almonertinib in Patients With Advanced Malignancies

Terminated
1
13
RoW
HRS2300, HRS2300、 SHR-1316, HRS2300、SHR-1701, HRS2300、trametinib, HRS2300、Almonertinib
Jiangsu HengRui Medicine Co., Ltd.
Advanced Malignancies
02/23
05/23
ChiCTR2000037927: An exploratory study of SHR-1701 in combination with Famitinib in patients with Advanced Pancreatic cancer and Biliary Tract Cancer

Recruiting
N/A
60
 
SHR-1701 + Famitinib
Fudan University Shanghai Cancer Center; Fudan University Shanghai Cancer Center, The research drug was provided by Hengrui Pharmaceutical
Pancreatic cancer and Biliary Tract Cancer
 
 
ChiCTR2100046099: Clinical trial of an umbrella study of precise treatment of bone and soft tissue sarcoma based on molecular pathways

Recruiting
N/A
51
 
SHR-1701+Famitinib ;Camrelizumab+SHR-6390 ;SHR-2554
Affiliated Sixth People's Hospital, Shanghai Jiaotong University; Affiliated Sixth People's Hospital, Shanghai Jiaotong University, self-funded
advanced bone and soft tissue sarcoma
 
 
ChiCTR2000037146: A multicenter, randomized controlled trial of SHR1701 combined with GEMOX in treatment of biliary malignant tumor

Not yet recruiting
N/A
169
 
SHR1701 combined with GEMOX ;GEMOX
Renji Hospital, Shanghai Jiaotong University School of Medicine; Renji Hospital, Shanghai Jiaotong University School of Medicine, self-financing
biliary tract carcinoma
 
 
ChiCTR2000036960: Multicenter clinical study on precision treatment of biliary tract carcinoma

Not yet recruiting
N/A
76
 
SHR1701 combined with GEMOX
Renji Hospital, Shanghai Jiaotong University School of Medicine; Renji Hospital, Shanghai Jiaotong University School of Medicine, self-financing
biliary tract carcinoma
 
 
ChiCTR2300072634: SHR1701 in combination with Surufatinib as late-line treatment in advanced colorectal cancer

Not yet recruiting
N/A
38
 
SHR1701 and Surufatinib ;SHR1701 and Surufatinib
Shanghai East Hospital; Shanghai East Hospital, Fund
colorectal cancer
 
 
ICT-HCC, NCT06893887: Individualized Comprehensive Treatment for Advanced Hepatocellular Carcinoma

Recruiting
N/A
300
RoW
FOLFOX4, Adebrelimab, Apatinib, Icaritin, SHR-1701, QL1706, Bevacizumab, HAIC, Local treatment, The original treatment regimen
Nanjing Tianyinshan Hospital
Hepatocellular Carcinoma(HCC)
03/27
03/28
ChiCTR2200062197: A Phase II clinical study of SHR-1701 combined with albumin paclitaxel and carboplatin in the treatment of advanced non-small cell lung cancer with malignant pleural effusion

Not yet recruiting
N/A
42
 
SHR-1701 combined with albumin paclitaxel and carboplatin
West China Hospital of Sichuan University; West China Hospital of Sichuan University, Research Fund From Hospital
Non-small cell lung cancer with malignant pleural effusion
 
 
niclosamide (ANA001) / Dong-A
NCT04603924: Study of Niclosamide in Moderate and Severe Hospitalized Coronavirus-19 (COVID-19) Patients

Completed
2/3
49
US
Niclosamide, ANA001, Placebo, Matching Placebo to ANA001
NeuroBo Pharmaceuticals Inc.
COVID-19
02/22
02/22
NCT04705415: A Single and Multiple Ascending Dose Study of Niclosamide in Healthy Volunteers

Completed
1
54
US
Niclosamide, ANA001, Placebo, Matching Placebo to ANA001
NeuroBo Pharmaceuticals Inc.
Healthy
10/21
10/22
NCT05188170: Niclosamide in Pediatric Patients With Relapsed and Refractory AML

Recruiting
1
16
US
Niclosamide
Stanford University
Acute Myeloid Leukemia (AML)
07/25
12/26
DA8010 / Dong-A
NCT05282069: A Study to Evaluate the Efficacy and Safety of DA-8010 in Patients With Overactive Bladder

Completed
3
607
RoW
DA-8010 Placebo, DA-8010 2.5mg, DA-8010 5mg, Solifenacin 5mg, Solifenacin succinate placebo
Dong-A ST Co., Ltd.
Overactive Bladder
11/23
05/24
NCT05992428: Drug Interactions When DA-8010 is Co-administered With Paroxetine or Mirabegron in Healthy Adults

Completed
1
37
RoW
DA-8010 5mg, Paroxetine 20mg, Mirabegron 50mg
Dong-A ST Co., Ltd.
Healthy
11/23
12/23
NCT05991401: Evaluate the Effect of Clarithromycin/Rifampicin on the Pharmacokinetics of DA-8010 in Healthy Adults

Completed
1
18
RoW
DA-8010 5mg, Clarithromycin 500mg, Rifampicin 600mg
Dong-A ST Co., Ltd.
Healthy
11/23
11/23
NCT05812417: A Study to Evaluate the Effects of Renal Function on Pharmacokinetics and Safety of DA-8010

Completed
1
33
RoW
DA-8010
Dong-A ST Co., Ltd.
Renal Impairment, Healthy
06/24
06/24
DA-2811 / Dong-A
NCT05743907: Clinical Trial to Evaluate the Efficacy and Safety of DA-2811 When Added to Ongoing Metformin Monotherapy in Patients with Type 2 Diabetes Who Have Inadequate Glycemic Control

Completed
4
231
RoW
DA-2811, Forxiga
Dong-A ST Co., Ltd.
Diabetes Mellitus
03/25
03/25
DA-4507 / Dong-A
No trials found

Download Options